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INTRODUCTION
In 1995, the US Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA)
developed guidelines for preventing opportunistic infections (OIs) in persons infected with human
immunodeficiency virus (HIV)1–3. These guidelines, written for health-care providers and patients, were
revised in 19974 and again in 19995. They have been published in the MMWR1,4,5, Clinical Infectious
Diseases2,6,7, the Annals of Internal Medicine3,8, the AmericanFamily Physician9,10, and Pediatrics11; accompany-
ing editorials have appeared in JAMA12,13. Response to these guidelines (e.g., the many requests for
reprints, numerous web site contacts and observations from health-care providers) suggests they have
served asavaluable referenceforHIV careproviders.Becausethe1995,1997and1999guidelinesincluded
ratings indicating the strength of each recommendation and the quality of supporting evidence, readers
have been able to assess the relative importance of each recommendation.
Since AIDS was first recognized 20 years ago, remarkable progress has been made in improving the
quality and duration of life of HIV-infected persons in the industrialized world. During the first decade of
the epidemic, this improvement occurred because of better recognition of opportunisticdisease processes,
better therapy for acute and chronic complications and the introduction of chemoprophylaxis against
important opportunistic pathogens. The second decade of the epidemic has witnessed extraordinary
progress in developing highly active antiretroviral therapies (HAART) as well as continuing progress in
preventing and treating individual OIs. HAART has reduced the incidence of OIs and extended life
substantially14–16. HAART is the most effective approach to preventing OIs and should be considered for
all HIV-infected persons who qualify for such therapy14–16. However, some patients are not ready or able
to takeHAARTand othershavetried HAARTregimens, buttherapy hasfailed.Suchpatientswill benefit
from prophylaxis against OIs15. In addition, prophylaxis against specific OIs continuesto provide survival
benefits even among persons who are receiving HAART15.
Since HAART was introduced in the United States in 1995,it has become increasingly clear
that chemoprophylaxis for OIs need not necessarily be life-long. Antiretroviral therapy can
restore immune function. The period of susceptibility to opportunistic processes continues to
be accurately indicated by the CD4+ T lymphocyte count for patients who are receiving
HAART. Thus, a strategy of stopping primary or secondary prophylaxis for certain patients
whose immunity has improved as a consequence of HAART seems logical. Stopping prophy-
lactic regimens can simplify treatment, reduce toxicity and drug interactions, lower cost of
care and potentially facilitate adherence to antiretroviral regimens.
Infect Dis Obstet Gynecol 2002;10:3–64
3In 1999, the USPHS/IDSA guidelines suggested that it may be safe to stop primary or
secondary prophylaxis for some (but not all) pathogens if HAART has led to an increase in
CD4+T lymphocytecountsabovespecified thresholdlevels.Recommendations weremade for
onlythosepathogens for whichadequate clinicaldatawereavailable.Datagenerated since1999
continue to support these recommendations and allow additional recommendations to be
madeconcerning thesafety ofstoppingprimary orsecondary prophylaxisforotherpathogens.
For recommendations on discontinuation of chemoprophylaxis, readers willnote thatcrite-
ria vary by such factors as duration of CD4+ T lymphocyte count increase, and, in the case of
secondary prophylaxis,duration of treatment of theinitialepisode of disease. Thesedifferences
reflect thecriteria used in specific studies. Therefore, some inconsistency in theformat of these
criteria is unavoidable.
Although considerable data are now available concerning discontinuing primary and
secondary OI prophylaxis, essentially no data are available regarding restarting prophylaxis
when the CD4+ T lymphocyte count decreases again to levels at which the patient is likely to
again be at risk for OI. For primary prophylaxis, whether to use the same threshold at which
prophylaxis may be stopped (derived from data in studies addressing prophylaxis discontinua-
tion), or to use the threshold below which initial prophylaxis is recommended is unknown.
Therefore in thisrevision of theguidelines, in some cases ranges are provided for restarting pri-
mary or secondary prophylaxis. For prophylaxis against Pneumocystis carinii pneumonia (PCP),
the suggested threshold for restarting both primary and secondary prophylaxis is 200 cells/ml.
For all these recommendations, the roman numeral ratings reflect the lack of data available to
assist in making these decisions (see description of rating system below).
During the development of these revised guidelines, working group members reviewed published
manuscripts as well as abstracts and material presented at professional meetings. A series of tele-
conferences wereheldtodevelop therevisions.Inthisrevision, information and recommenda-
tions which are new since the 1999 publication are indicated in bold.
MAJOR CHANGES IN THESE RECOMMENDATIONS
Major changes in the guidelines since 1999 include:
1. Higher level ratings have been provided for discontinuing primary prophylaxis for
PCP and MAC when CD4+ T lymphocytes have increased to > 200 cells/ml and
> 100 cells/ml, respectively, for 3 months in response to HAART (AI), and a new recom-
mendation to discontinue primary toxoplasma prophylaxis has been provided when the
CD4+ T lymphocyte count has increased to > 200 cells/ml for 3 months (AI).
2. Secondary PCP prophylaxis should be discontinued in patients whose CD4+ counts have
increased to > 200 cells/ml for 3 months as a consequence of HAART (BII).
3. Secondary prophylaxis for disseminated MAC may be discontinued in patients with a
sustained (e.g., 6 months) increase in CD4+ count to > 100 cells/ml in response to
HAART if they have completed 12 months of MAC therapy and have no symptoms or
signs attributable to MAC (CIII).
4. Secondary prophylaxis for toxoplasmosis and cryptococcosis may be discontinued in
patients with a sustained increase in CD4+ counts (e.g. 6 months) to > 200 cells/ml and
> 100–200 cells/ml respectively, in response to HAART if they have completed their
initial therapy and have no symptoms or signs attributable to these pathogens (CIII).
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emphasized (BIII).
6. Additional information about transmission of human herpes virus 8 infection (HHV-8) is
provided.
7. New information on drug interactions is provided, especially with regard to rifamycins
and antiretroviral drugs.
8. Revised recommendations for immunization of HIV exposed/infected adults and
children are provided.
HOW TO USE THE INFORMATION IN THIS REPORT
For each of the 19 diseases covered in this report, specific recommendations are provided that address
a) prevention of exposure to the opportunistic pathogen, b) prevention of the first episode of disease and
c) prevention of disease recurrence. Recommendations are rated by a revised version of the IDSA rating
system17. In this system, theletters A–E signify thestrengthoftherecommendationfororagainst a preven-
tive measure and roman numerals I–III indicate the quality of evidence supporting the recommendation
(see Table 1).
This report incldes a number of tables that summarize recommendations. They are as follows: dosages
for prophylaxis to prevent first episode of opportunistic disease in HIV infected adults and adolescents
(Table 2); dosages for prophylaxis to prevent recurrence of opportunistic disease in HIV-infected adults
and adolescents (Table 3); effects of food on drugs used to treat OIs (Table 4); effects of medications on
drugs used to treat OIs (Table 5); effects of OI medications on drugs commonly administered to
HIV-infectedpersons(Table6);adverse effectsofdrugsusedtomanageHIVinfection(Table7);dosagesof
drugsforprevention ofOIsforpersonswith renalinsufficiency(Table 8);costsofagents recommended for
the prevention of OIs in adults with HIV infection (Table 9); immunologic categories for HIV-infected
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Rating Strength of the recommendation
A
B
C
D
E
I
II
III
Both strong evidence for efficacy and substantial clinical benefit support recommendation for use. Should always
be offered
Moderate evidence for efficacy – or strong evidence for efficacy but only limited clinical benefit – supports
recommendation for use. Should generally be offered
Evidence for efficacy is insufficient to support a recommendation for or against use. Or evidence for efficacy might
not outweigh adverse consequences (e.g.,drug toxicity, drug, interactions) or cost of the chemoprophylaxis or
alternative approaches. Optional
Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should
generally not be offered
Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never
be offered
Quality of evidence supporting the recommendation
Evidence from at least one properly randomized, controlled trial
Evidence from at least one well-designed clinical trial without randomization, from cohort or case-controlled
analytic studies (preferably from more than one center), or from multiple time-series studies. Or dramatic results
from uncontrolled experiments
Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of
expert committees
Table 1 System used to rate the strength and quality of evidence supporting recommendations for prevention of
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Preventive regimens
Pathogen Indication First choice Alternatives
I. Strongly recommended
as standard of care
Pneumocystis carinii1
CV4+ count < 200/ml or
oropharyngeal candidiasis
Trimethoprim-sulfamethoxa
zole (TMP-SMZ), 1 DS po
q.d. (AI)
TMP-SMZ, 1 SS po q.d. (AI)
Dapsone, 50 mg po b.i.d. or
100 mg po q.d. (BI);
dapsone, 50 mg po q.d. plus
pyrimethamine, 50 mg po
q.w. plus leucovorin 25 mg
po q.w. (BI); dapsone
200 mg po plus
pyrimethamine, 75 mg po
plus leucovorin, 25 mg po
q.w. (BI); aerosolized
pentamidine, 300 mg q.
month via Respirgard IIÔ
nebulizer (BI); atovaquone,
1500 mg po q.d. (BI); TMP-
SMZ, 1 DS po t.i.w. (BI)
Mycobacterium tuberculosis
Isoniazid-sensitive2
Isoniazid-resistant
Multidrug-(isoniazid and
rifampin) resistant
TST reaction ‡ 5 mm or
prior positive TST result
without treatment or
contact with case of active
tuberculosis regardless of
TST result (BIII)
Same as above; high
probability of exposure to
isoniazid-resistant
tuberculosis
Same as above; high
probability of exposure to
multidrug-resistant
tuberculosis
Isoniazid, 300 mg po plus
pyridoxine, 50 mg po
q.d. ´ 9 mo (AII) or isoniazid,
900 mg po plus pyridoxine,
100 mg po b.i.w. ´ 9 mo
(BII); rifampin, 600 mg plus
pyrazinimide, 15–20 mg/kg
po q.d. ´ 2 mo (AI)
Rifampin 600 mg plus
pyrazinamide, 15–20 mg/kg
po q.d. ´ 2 mo (AI)
Choice of drugs requires
consultation with public
health authorities. Depends
on susceptibility of isolate
from source patient
Rifabutin 300 mg po q.d. plus
pyrazinamide, 15–20 mg/kg
po q.d. ´ 2 mo (BIII);
rifampin 600 mg po
q.d. ´ 4 mo (BIII)
Rifabutin, 300 mg plus
pyrazinamide 15–20 mg/kg
po q.d. ´ 2 mo (BIII);
rifampin, 600 mg po
q.d. ´ 4 mo (BIII); rifabutin,
300 mg po q.d. ´ 4 mo (CIII)
—
Toxoplasma gondii3 IgG antibody to Toxoplasma
and CD4+ count < 100/ml
TMP-SMZ, 1 DS po q.d. (AII) TMP-SMZ, 1 SS po q.d.
(BIII); dapsone, 50 mg po
q.d. plus pyrimethamine,
50 mg po q.w. plus
leucovorin, 25 mg po q.w.
(BI); atovaquone, 1500 mg
po q.d. with or without
pyrimethamine, 25 mg po
q.d. plus leucovorin, 10 mg
po q.d. (CIII)
Table 2 Prophylaxis to prevent first episode of opportunistic disease in adults and adolescents infected with human
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Mycobacterium avium
complex4
CD4+ count < 50/ml Azithromycin, 1200 mg po
q.w., (AI) or clarithromycin*,
500 mg po b.i.d. (AI)
Rifabutin, 300 mg po q.d.
(BI); azithromycin, 1,200 mg
po q.w. plus rifabutin,
300 mg po q.d. (CI)
Varicella zoster virus (VZV) Significant exposure to
chickenpox or shingles for
patients who have no history
of either condition or, if
available, negative antibody
to VZV
Varicella zoser immune
globulin (VZIG), 5 vials
(1.25 ml each) im,
administered £ 96 h after
exposure, ideally within 48 h
(AIII)
II. Generally
Recommended
Streptococcus pneumoniae5 CD4
+ count ‡ 200/ml 23 valent polysaccharide
vaccine, 0.5 ml im [BII]
None
Hepatitis B virus6,7 All susceptible
(anti-HBc-negative) patients
Hepatitis B vaccine: 3 doses
(BII)
None
Influenza virus6,8 All patients (annually, before
influenza season)
Inactivated trivalent
influenza virus vaccine one
annual dose (0.5 ml) im
(BIII)
Oseltamivir, 75 mg po
q.d. (influenza A or B)
(CIII); rimantadine, 100 mg
po b.i.d. (CIII), or
amantadine, 100 mg po b.i.d.
(CIII) (influenza A only)
Hepatitis A virus6 All susceptible
(anti-HAV-negative) patients
at increased risk for HAV
infection (e.g., illicit drug
users, men who have sex
with men, hemophiliacs)
or with chronic liver
disease, including chronic
hepatitis B or hepatitis C
Hepatitis A vaccine: two
doses (BIII)
None
III. Evidence for Efficacy
but Not Routinely
Indicated
Bacteria
Neutropenia Granulocyte-colony-
stimulating factor (G-CSF),
5–10 mg/kg sc q.d. ´ 2–4 w
or granulocyte-macrophage
colony-stimulating factor
(GM-CSF), 250 mg/m2 sc
iv ´ 2–4 w (CII)
None
Cryptococcus neoformans CD4+ count < 50/ml Fluconazole, 100–200 mg po
q.d. (CI)
Itraconazole capsule,
200 mg po q.d. (CIII)
Table 2 Continued2001 USPHS/IDSA guidelines US Public Health Service
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Histoplasma Capsulatum9 CD4+ count < 100/ml,
endemic geographic area
Itraconazole capsule, 200 mg
po q.d. (CI)
None
Cytomegalovirus (CMV)10 CD4+ count < 50/ml and
CMV antibody positivity
Oral ganciclovir, 1g po t.i.d.
(CI)
None
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling
for the particular products or indications in question. Specifically, the terms ‘safe’ and ‘effective’ might not be synonymous with the
FDA-defined legal standards for product approval. The Respirgard IIÔ nebulizer is manufactured by Marquest, Englewood, Colorado.
Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendation and the quality of evidence
supporting it (see Table 1).
ABBREVIATIONS: Anti-HBc = antibody to hepatitis B core antigen; b.i.w. = twice a week; DS = double-strength tablet; HAART = highly
active antiretroviral therapy; HAV = hepatitis A virus; HIV = human immunodeficiency virus; im = intramuscular; iv = intravenous;
po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly; SS = single-strength tablet; t.i.w. = three times a week;
TMP-SMZ = trimethoprim-sulfamethoxazole; sc = subcutaneous; and TST = tuberculin skin test.
1Prophylaxis should also be considered for persons with a CV4+ percentage of < 14%, for persons with a history of an AIDS-defining
illness, and possibly for those with CD4+ counts > 200 but < 250 cells/ml. TMP-SMZ also reduces the frequency of toxoplasmosis and
some bacterial infections. Patients receiving dapsone should be tested for glucose-6 phosphate dehydrogenase deficiency. A dosage of
50 mg q.d. is probably less effective than 100 mg q.d. The efficacy of parenteral pentamidine (e.g. 4 mg/kg/month) is uncertain. Fansidar
(sulfadoxine-pyrimethamine) is rarely used because of severe hypersensitivity reactions. Patients who are being administered therapy for
toxoplasmosis with sulfadiazine-pyrimethamine are protected against Pneumocystis carinii pneumonia and do not need additional prophylaxis
against PCP.
2Directly observed therapy is recommended for isoniazid, e.g., 900 mg b.i.w.; isoniazid regimens should include pyridoxine to prevent
peripheral neuropathy. If rifampin or rifabutin are administered concurrently with protease inhibitors or non-nucleoside reverse
transcriptase inhibitors, careful consideration should be given to potential pharmacokinetic interactions (54). See discussion
of rifamycin interactions in paragraph 11 in section on Tuberculosis. Exposure to multidrug-resistant tuberculosis might require
prophylaxis with two drugs; consult public health authorities. Possible regimens include pyrazinamide plus either ethambutol or a
fluoroquinolone.
3Protection against toxoplasmosis is provided by TMP-SMZ, dapsone plus pyrimethamine, and possibly by atovaquone. Atovaquone may be
used with or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection.
4See paragraph 9, in section on ‘Disseminated Infection with Mycobacterium avium complex and references 53–54 for
discussion of drug interactions.
5Vaccination may be offered to persons who have a CD4
+ T-lymphocyte count < 200 cells/ml, although the efficacy is likely to be
diminished. Revaccination 5 years after the first dose or sooner if the initial immunization was given when the CD4
+ count was
< 200 cells/ml and the CD4
+ count has increased to > 200 cells/ml on HAART is considered optional. Some authorities are concerned that
immunizations might stimulate the replication of HIV.
6Data do not conclusively demonstrate clinical benefit of these vaccines in this population, although it is logical to assume that those patients
who develop antibody responses will derive some protection. Some authorities are concerned that immunizations might stimulate HIV
replication, although for influenza vaccination, a large observational study of HIV-infected persons in clinical care showed no adverse effect
of this vaccine, including multiple doses, on patient survival (J. Ward, CDC, personal communication). Also, this concern may be less
relevant in the setting of HAART. However, because of the theoretical concern that increases in HIV plasma RNA following
vaccination during pregnancy might increase the risk of perinatal transmission of HIV, providers may wish to defer
vaccination for such patients until after HAART is initiated.
7Hepatitis B vaccine has been recommended for all children and adolescents and for all adults with risk factors for hepatitis B
virus (HBV).
8Oseltamivir is appropriate during outbreaks of either influenza A or influenza B. Rimantadine and amantadine are
appropriate during outbreaks of influenza A (although neither rimantadine nor amantadine is recommended during
pregnancy). Dosage reduction for antiviral chemoprophylaxis against influenza might be indicated for decreased renal or
hepatic function, and for persons with seizure disorders. Physicians should consult the frug package inserts and the annual
CDC influenza guidelines for more specific information about adverse effects and dosage adjustments. For additional information
regarding vaccination against hepatitis A and B and vaccination and antiviral therapy against influenza see CDC. Prevention of hepatitis A
through active or positive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR
1999;48(No. RR-12); CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal
childhood vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1991;40(No. RR-13); and
CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). For
additional information about vaccination and antiviral therapy against influenze see: CDC, Prevention and Control of
Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;50(No. RR-4).
9In a few unusual occupational or other circumstances, prophylaxis should be considered; consult a specialist.
10. Acyclovir is not protective against CMV. Valacyclovir is not recommended because of an unexplained trend toward increased mortality
observed in persons with AIDS who were being administered this drug for prevention of CMV disease.
*During pregnancy, azithromycin is preferred over clarithromycin because of the teratogenicity in animals of clarithromycin.
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Preventive Regimens
Pathogen Indication First Choice Alternatives
Recommended as standard of care
Pneumocystis carinii Prior P. carinii pneumonia Trimethoprim-sulfamethox
azole (TMP-SMZ), 1 DS po
q.d. (AI);
TMP-SMZ 1 SS po q.d. (AI)
Dapsone, 50 mg po b.i.d. or
100 mg po q.d. (BI); dapsone,
50 mg po q.d. plus
pyrimethamine, 50 mg po q.w.
plus leucovorin, 25 mg po q.w.
(BI); dapsone, 200 mg po plus
pyrimethamine, 75 mg po plus
leucovorin, 25 mg po q.w. (BI);
aerosolized pentamidine,
300 mg q.m. via Respirgard IIä
nebulizer (BI); atovaquone,
1500 mg po q.d. (BI); TMP-SMZ,
1 DS po t.i.w. (CI)
Toxoplasma gondii1 Prior toxoplasmic
encephalitis
Sulfadiazine, 500–1,000 mg
po q.i.d. plus
pyrimethamine, 25–50 mg
po q.d. plus leucovorin,
10–25 mg po q.d. (AI)
Clindamycin, 300–450 mg po q
6–8 h plus pyrimethamine,
25–50 mg po q.d. plus,
leucovorin 10–25 mg po q.d.
(BI); atovaquone 750 mg po q
6–12 h with or without
pyrimethamine, 25 mg po q.d.
plus leucovorin, 10 mg po, q.d.
(CIII)
Mycobacterium avium
complex2
Documented disseminated
disease
Clarithromycin*, 500 mg
po b.i.d. (AI) plus
ethambutol, 15 mg/kg po
q.d. (AII); with or without
rifabutin, 300 mg po q.d.
(CI)
Azithromycin, 500 mg po q.d.
(AII) plus ethambutol, 15 mg/kg
po q.d. (AII); with or without
rifabutin, 300 mg po q.d. (CI)
Cytomegalovirus Prior end-organ disease Ganciclovir, 5–6 mg/kg/day
iv 5–7 days/wk or 1,000 mg
po t.i.d. (AI); or foscarnet,
90–120 mg/kg iv q.d. (AI);
or (for retinitis) ganciclovir
sustained-release implant q
6–9 months plus
ganciclovir, 1.0–1.5 g po
t.i.d. (AI);
Cidofovir, 5 mg/kg iv q.o.w. with
probenecid 2 grams po 3 hours
before the dose followed by 1
gram po 2 hours after the dose,
and 1 gram po 8 hours after the
dose (total of 4 grams) (AI).
Fomivirsen 1 vial (330 mg)
injected into the vitreous, then
repeated every 2–4 wks (AI);
valganciclovir 900 mg po q.d.
(BI)
Cryptococcus neoformans Documented disease Fluconazole, 200 mg po
q.d. (AI)
Amphotericin B, 0.6–1.0 mg/kg
iv q.w.–t.i.w. (AI); itraconazole,
200 mg po q.d. (BI)
Histoplasma capsulatum Documented disease Itraconazole capsule,
200 mg po b.i.d. (AI)
Amphotericin B, 1.0 mg/kg iv
q.w. (AI)
Table 3 Prophylaxis to prevent recurrence of opportunistic disease in adults (after chemotherapy for acute disease)
in adults and adolescents infected with human immunodeficiency viruschildren(Table 10); immunization scheduleforHIV-infected children (Table 11); dosages for prophylaxis
topreventfirstepisodeofopportunisticdisease inHIV-infected infantsandchildren(Table12);dosagesfor
prophylaxistopreventrecurrenceofopportunisticdisease inHIV-infected infantsand children(Table 13);
and criteria for discontinuing and restarting OI prophylaxis for adult patients with HIV infection
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Coccidioides immitis Documented disease Fluconazole, 400 mg po
q.d. (AII)
Amphotericin B, 1.0 mg/kg iv
q.w. (AI); itraconazole, 200 mg
capsule po b.i.d. (AII)
Salmonella species,
(non-typhi)3
Bacteremia Ciprofloxacin, 500 mg po
b.i.d. for several months
(BII)
Antibiotic chemoprophylaxis
with another active agent (CIII)
II. Recommended only if subsequent episodes are frequent or severe
Herpes simplex virus Frequent/severe
recurrences
Acyclovir, 200 mg po t.i.d.
or 400 mg po b.i.d. (AI)
Famciclovir 500 mg po
b.i.d. (AI)
Valacyclovir, 500 mg po b.i.d.
(CIII)
Candida (oropharyngeal or
vaginal)
Frequent/severe
recurrences
Fluconazole 100–200 mg
po q.d. (CI)
Itraconazole solution, 200 mg po
q.d. (CI);
Candida (esophageal) Frequent/severe
recurrences
Fluconazole 100–200 mg
po q.d. (BI)
Itraconazole solution, 200 mg po
q.d. (BI);
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling
for the particular products or indications in question. Specifically, the terms ‘safe’ and ‘effective’ might not be synonymous with the
FDA-defined legal standards for product approval. The Respirgard IIÔ nebulizer is manufactured by Marquest, Englewood, Colorado.
Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendation and the quality of evidence
supporting it (see Table 1).
ABBREVIATIONS: b.i.d. = twice a day; DS = double-strrength tablet; po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly;
q.o.w. = every other week; SS = single-strength tablet; t.i.d. = three times a day; t.i.w. = three times a week; and
TMP-SMZ = trimethoprim-sulfamethoxazole.
1Pyrimethamine-sulfadiazine confers protection against PCP as well as toxoplasmosis; clindamycin-pyrimethamine does not offer
protection against PCP.
2Many multiple-drug regimens are poorly tolerated. Drug interactions (e.g., those seen with clarithromycin and rifabutin) can be
problematic; rifabutin has been associated with uveitis, especially when administered at daily doses of > 300 mg or concurrently with
fluconazole or clarithromycin. See discussion of rifamycin interactions in paragraph 9 in section on Tuberculosis (54).
3Efficacy for eradication of Salmonella has been demonstrated only for ciprofloxacin.
*During pregnancy, azithromycin is recommended instead of clarithromycin because clarithromycin is teratogenic in animals.
Table 3 Continued
Drug Food effect Recommendation
Atovaquone
Ganciclovir (capsules)
Itraconazole
Itraconazole (capsules)
Itraconazole (solution)
Bioavailability increased up to threefold with high-fat
meal.
High-fat meal results in 22% increase in AUC.
Grapefruit juice results in 30% decrease in AUC.
Significant increase in bioavailability when taken with a
full meal.
31% increase in AUC when taken under fasting
conditions
Administer with food.
Administer with food.
Avoid concurrent grapefruit juice
Administer with food.
Take without food if possible.
Table 4 Effects of Food on Drugs used to prevent opportunistic infections2001 USPHS/IDSA guidelines US Public Health Service
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Affected drug Interacting drug(s) Mechanism/effect Recommendations
Atovaquone Rifampin Induction of metabolism –
decreased drug levels
Concentrations might not
be therapeutic; avoid
combination or increase
atovaquone dose
Atovaquone Lopinavir-ritonavir Potential for induction of
metabolism – decreased
drug levels
Concentrations may not
be therapeutic – may
require increase
atovaquone dose
Clarithromycin Efavirenz Induction of metabolism
– decrease in
clarithromycin AUC by
39%, increase in AUC of
14-OH clarithromycin by
34%
Clarithromycin efficacy
uncertain
Clarithromycin Ritonavir Inhibition of metabolism
– increased
clarithromycin drug
levels by 77%
Dose adjustment of
clarithromycin necessary
only if renal dysfunction
is present. For CrCl
< 60 ml/min, reduce
clarithromycin dose by
50%; for CrCl
< 30 ml/min, reduce
dose by 75%
Clarithromycin Lopinavir-Ritonavir Inhibition of metabolism
– increased
clarithromycin drug
levels
Clarithromycin Nevirapine Induction of metabolism –
decrease in clarithromycin
AUC by 35%, increase in
AUC of 14-OH
clarithromycin by 27%
Efficacy of MAC
prophylaxis may be
decreased; monitor closely
Ketoconazole Lopinavir-ritonavir Inhibition of metabolism,
increased ketonconazole
AUC
Use with caution at
ktoconazole doses
> 200 mg/day
Ketoconazole Antacids, didanosine,
Buffered products,
H2-blockers, proton Pump
inhibitors
Increase in gastric pH that
impairs absorption of
ketoconazole
Avoid use of ketoconazole
with pH-raising agents or
use alternative antifungal
drug
Quinolone antibiotics
(ciprofloxacin, levofloxacin,
gatifloxacin,
Moxifloxacin)
Didanosine, antacids, iron
products, calcium products,
sucralfate (cation
preparations)
Chelation results in marked
decrease in quinolone drug
levels
Administer cation
preparation at least 2
hours after quinolone
Table 5 Effects of medications on drugs used to prevent opportunistic infections(Table 14). Recommendations advising patients how to prevent exposure to opportunistic pathogens
appear in the Appendix at the end of this report.
This report is oriented toward the prevention of specific OIs in HIV-infected persons in the United
States and other industrialized countries. Recommendations for use of HAART, which is designed to
prevent immunologic deterioration, to restore immune function and delay the need for many of
the chemoprophylactic strategies described in this report, were originally published elsewhere14 and
are updated regularly (www.hivatis.org)16.
Pamphlets for patients regarding prevention of OIs can be obtained from the HIV/AIDS
Treatment Information Service (ATIS) by calling (800) 448-0440, (301) 519-0459 (inter-
national) or (888) 480-3739(TTY). They also can be accessed on both the CDC and HIVATIS
websites (www.cdc.gov/hiv/pubs/brochure.htm and www.hivatis.org).
New data on prevention of OIs in HIV-infected persons are emerging, and randomized controlled
trials addressing some unresolved issues in OI prophylaxis are ongoing. The OI Working Group review
emerging data routinely and will update these guidelines on a regular basis.
PNEUMOCYSTIS CARINII PNEUMONIA
Prevention of exposure
Although some authorities recommend that persons with HIV infection who are at risk for P. carinii
pneumonia (PCP) not share a hospital room with a patient who has PCP, data are insufficient to support
this recommendation as standard practice (CIII).
Prevention of disease
Initiation of primary prophylaxis
Adults and adolescents who have HIV infection (including pregnant women and those on HAART)
should receive chemoprophylaxis against PCP if they have a CD4+ T lymphocyte count of less than
200 ml (AI) or a history of oropharyngeal candidiasis (AII)18–20. Persons who have a CD4+ T lymphocyte
percentageofless than 14% orhistoryof an acquired immunodeficiencysyndrome(AIDS)-defining illness
butdo nototherwise qualify should be considered for prophylaxis (BII)18–20. When monitoring the CD4+
T lymphocyte count at least every 3 months is not possible, initiation of chemoprophylaxis at a CD4+
T lymphocyte count of greater than 200 but less than 250 cells/ml also should be considered (BII)19.
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Rifabutin Fluconazole Inhibition of metabolism –
marked increase in rifabutin
drug levels
Monitor for rifabutin
toxicities such as uveitis,
nausea, neutropenia.
Rifabutin Efavirenz Induction of metabolism –
significant decrease in
rifabutin AUC
Increase rifabutin dose to
450–600 mg daily or
600 mg twice weekly*
Rifabutin Ritonavir,
lopinavir-ritonavir
Inhibition of metabolism
– marked increase in
rifabutin drug levels
Decrease rifabutin to
150 mg every other day
or three times per week.
Rifabutin Indinavir, nelfinavir,
amprenavir
Inhibition of metabolism
– marked increase in
rifabutin drug levels
Decrease rifabutin to
150 mg qd or 300 mg
twice weekly
*Appropriate dose of efavirenz is uncertain if a protease inhibitor is used with efavirenz plus rifabutin
Table 5 ContinuedTrimethoprim-sulfamethoxazole (TMP-SMZ) is the recommended prophylactic agent (AI)20–23. One
double-strengthtablet perdayis thepreferred regimen (AI)23. However,onesingle-strength tabletper day
is also effective and might be better tolerated than one double strength tablet per day (AI). One
double-strength tablet three times per week is also effective (BI)24. TMP-SMZ at a dose of one
double-strengthtabletperdayconferscross-protectionagainst toxoplasmosis25and somecommon respira-
tory bacterial infections21,26. Lower doses of TMP-SMZ also might confer such protection. For patients
whohave an adverse reaction that is notlife-threatening, treatment with TMP-SMZ shouldbe continued
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Affected drug Interacting drug(s) Mechanism (effect) Recommendation
Amprenavir, delavirdine,
indinavir, lopinavir-ritonavir,
nelfinavir, saquinavir
Rifampin Induction of metabolism –
marked decrease in
protease inhibitor or
delavirdine drug levels
Avoid concomitant use
Efavirenz, ritonavir,
ritonavir-saquinavir,
nevirapine
Rifampin Induction of metabolism:
decrease in protease or
nevirapine levels
Combinations could
possibly be used but
limited clinical
experience. Consider
efavirenz 800 mg q.d.
when used with rifampin
Delavirdine Rifabutin Induction of metabolism
– 50–60% decrease in
delavirdine levels
Avoid concomitant use
Indinavir, nelfinavir,
amprenavir*
Rifabutin Induction of metabolism
– 50% decrease in
protease inhibitor levels
Consider increase in
indinavir dose to
1000 mg q8h; If indinavir
is the sole protease
inhibitor decrease
rifabutin dose to 150 mg
q.d.
Ritonavir Rifabutin Induction of metabolism
of Ritonavir
Consider rifabutin
150 mg q.o.d. or twice
weekly
Efavirenz Rifabutin Potential for decreased
efavirenz levels
No dosage change
necessary for efavirenz;
adjust rifabutin dose to
450–600 mg qd or
600 mg twice daily
Saquinavir Rifabutin Potential for decreased
saquinavir levels
Limited data
Didanosine Ganciclovir (po) Increased ddI AUC by
approximately 100%
Clinical significance
unknown; monitor for
ddI-related adverse effects
*Little data are available for use of rifamycin drugs with ritonavir-boosting protease inhibitor regimens except for
ritonavir-saquinavir and ritonavir-lopinavir. Therefore, concomitant use of rifamycins with these regimens must be
approached cautiously
Table 6 Effects of opportunistic infection medications on antiinfective drugs commonly administered to persons
infected with human immunodeficiency virus*if clinically feasible; for those who have discontinued such therapy because of an adverse reaction,
reinstitution of TMP-SMZ should be strongly considered after the adverse event has resolved (AII).
Patients who have experienced adverse events, especially fever and rash, might better tolerate reintroduc-
tion of the drug with a gradual increase in dose (desensitization) as per published regimens (BI)27,28 or
reintroductionofTMP-SMZat areduceddoseorfrequency(CIII); upto70%ofpatientscantoleratesuch
reinstitution of therapy26.
If TMP-SMZ cannot be tolerated, prophylactic regimens that can be recommended as alternatives
include dapsone (BI)21, dapsone plus pyrimethamine plus leucovorin (BI)29,30, aerosolized pentamidine
administered bytheRespirgard IITM nebulizer(Marquest, Englewood,Colorado)(BI)22andatovaquone
(BI)31,32. Atovaquone appears to be as effective as aerosolized pentamidine31 or dapsone (BI)32 but is sub-
stantially more expensive than the other regimens. For patients seropositive for Toxoplasma gondii who
cannot tolerate TMP-SMZ, recommended alternatives to TMP-SMZ for prophylaxis against both PCP
and toxoplasmosis include dapsone plus pyrimethamine (BI)29,30 or atovaquone with or without
pyrimethamine (CIII). The following regimens generally cannot be recommended as alternatives because
data regarding their efficacy for PCP prophylaxis are insufficient for a firm recommendation: aerosolized
pentamidine administered by other nebulization devices, intermittently administered parenteral pentami-
dine, oral pyrimethamine plus sulfadoxine, oral clindamycin plus primaquine and intravenous
trimetrexate. However, clinicians may consider using these agents in unusual situations in which the
recommended agents cannot be administered (CIII).
Discontinuation of primary prophylaxis
Primary pneumocystis prophylaxis should be discontinued in adult and adolescent patients
who have responded to HAART with an increase in CD4+ T lymphocyte counts to
> 200 cells/ml for at least 3 months (AI). In observational and randomized studies supporting
this recommendation, most patients were taking antiretroviral regimens that included a
protease inhibitor and most had a CD4+ T lymphocyte count greater than 200 cells/ml for at
least 3 months before discontinuation of PCP prophylaxis33–41. The median CD4+ lymphocyte
count at the time prophylaxis was discontinued was > 300 cells/ml, and many patients had a
sustained suppression of HIVplasma RNA levels below detection limitsof theassay employed.
Median follow-up ranged from 6–16 months.
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Bone Marrow Suppression
Diarrhea
Hepatotoxicity
Nephrotoxicity
Ocular Effects
Pancreatitis
Peripheral Neuropathy
Neurotoxicity
Skin Rash
Cidofovir, dapsone, ganciclovir, pyrimethamine, rifabutin, sulfadiazine, TMP-SMX
Atovaquone, clindamycin
Clarithromycin, fluconazole, isoniazid, itraconazole, ketoconazole, pyrazinamid, rifabutin,
rifampin, TMP-SMX
Amphotericin B, cidofovir, foscarnet, pentamidine, high dose acyclovir
Cidofovir, ethambutol, rifabutin
Pentamidine, TMP-SMX
Isoniazid
Acyclovir (high-dose), quinolones
Atovaquone, dapsone, pyrimethamine, sulfadiazine, TMP-SMX, ribaviron
Table 7 Adverse effects of drugs used in the prevention of opportunistic infections2001 USPHS/IDSA guidelines US Public Health Service
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Drug Normal dose Renal dysfunction
Acyclovir 200 mg–800 mg BID –
5 ´ day
Regimen
200 mg PO TID
400 mg PO q12h
hemodialysis:
CrCl (ml/min/1.73m2)
< 10
< 10
Adjusted Dose
200 mg q12h
200 mg q12h
additional dose after each
dialysis
Cidofovir 5 mg/kg IV every other
week (with probenecid
and hydration)
Reduce from 5 mg/kg to 3 mg/kg for an increase in serum creatinine of
0.3–0.4 above baseline. Discontinue for an increase in creatinine ‡ 0.5
above baseline or development of 3+ proteinuria.
Not recommended for patients with baseline serum creatinine > 1.5,
CrCl £ 55 ml/min, or ‡ 2+ proteinuria
Ciprofloxacin 500 mg PO q 12 hr CrCl (ml/min/1.73m2)
30–50
< 30
hemodialysis:
Dose
250 mg–500 mg q 12 hrs
250 mg–500 mg q 18 hrs
250–500 mg after dialysis
Clarithromycin 500 mg BID Reduce dose by one-half or double interval if creatinine clearance
< 30 ml/min
Famciclovir 250–500 mg q 12 h CrCl
20–39
< 20
hemodialysis:
Dose
125–250 mg q 12 h
125–250 mg q 24 h
125 mg after each dialysis
Fluconazole 50 mg–400 mg qd CrCl
< 50 (not on dialysis)
dialysis
Dose
1/2 dose
Full dose after dialysis
Valganciclovir 900 mg qd CrCl
40–59
25–39
10–24
< 10
Dialysis
Dose
450 mg qd
450 mg qd
450 mg twice weekly
not recommended
not recommended
Foscarnet 90–120 mg/kg/day CrCl
(ml/min/kg)
> 1.4
1.0–1.4
0.8–1.0
0.6–0.8
0.5–0.6
0.4–0.5
< 0.4
Maintenance
Low Dose
90 mg q 24 h
70 mg q 24 h
50 mg q 24 h
80 mg q 48 h
60 mg q 48 h
50 mg q 48 h
not recommended
High Dose
120 mg q 24 h
90 mg q 24 h
65 mg q 24 h
104 mg q 48 h
80 mg q 48 h
65 mg q 48 h
not recommended
Table 8 Dosing of drugs for primary prevention or maintenance therapy for opportunistic infections in renal
insufficiency*Discontinuation of primary prophylaxis in these patients isrecommended not onlybecause
prophylaxis appears to add very little to disease prevention (for PCP, toxoplasmosis, or bacte-
rial infections), but also because discontinuation of drug reduces pill burden, the potential for
drug toxicity, drug interactions, selection of drug-resistant pathogens and cost.
Restarting primary prophylaxis
Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to
< 200 cells/ml (AIII).
Prevention of recurrence
Patients who have a history of PCP should be administered chemoprophylaxis (i.e., secondary
prophylaxis or chronic maintenance therapy) with the regimens listed in Table 3 for life (AI)
unless immune reconstitution occurs as a consequence of HAART.
Discontinuation of secondary prophylaxis (Chronic maintenance therapy (CMT))
Secondary prophylaxis should bediscontinued for adult and adolescent patients whose CD4+T
cell count has increased from < 200 cells ml to > 200 cells/ml for at least 3 months due to
HAART (BII).Reports from observational studies37,41,42and from a randomized trial39, as well
as a combined analysis of eight European cohorts being followed prospectively43, support this
recommendation. Inthesestudies,patientshadresponded toHAARTwithanincrease inCD4+
T lymphocyte count to > 200 cells/ml for at least 3 months. Most patients were taking protease
inhibitor-containing regimens. The median CD4+ T lymphocyte count at the time prophy-
laxis was discontinued was > 300 cells/ml. Most patients had sustained suppression of HIV
plasma HIVRNA levelsbelow thedetectionlimitsoftheassay employed; thelongestfollow-up
was 13months.If theepisode of PCP occurred at a CD4+T lymphocytecount > 200 cells/ml,it
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Ganciclovir Oral:
1 gram TID (capsules)
IV:
5 mg/kg QD or 6 mg/kg
QD ´ 5 days/week (IV)
CrCl (ml/min)
50–69
25–49
10–24
< 10
IV dose (mg/kg)
2.5 q 24 h
1.25 q 24 h
0.625 q 24 h
0.625 TIW
Capsules
1500 mg qd or 500 mg
tid
1000 mg qd or 500 mg
bid
500 mb qd
500 mg TIW after dialysis
Levofloxacin 250 mg–500 mg QD CrCl (ml/min)
50–80
< 50
Dose
500 mg LD, then 250 mg q 24 hrs
500 mg LD, then 250 mg q 48 hrs
TMP/SMX 1 DS QD
1 DS TIW
1 SS QD
CrCl (ml/min)
15–30
< 15
Dose
1/2 dose
?
Valacyclovir 500 mg–1 gm q 24 h CrCl (ml/min/1.73m2)
< 30
Dose
500 mg q 24–48 h
ABBREVIATIONS: b.i.d. = twice daily; CrCl = creatinine clearance; DS = double-strength tablet; iv = intravenous; l.d. = loading dose;
q.d. = daily; q.o.w. = every other week; SS = single-strength tablet; t.i.d. = three times daily; t.i.w. = three times a week.
*Creatinine clearance for foscarnet is expressed as ml/min/kg
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Opportunistic pathogen Drug/Vaccine Dose
Annual Cost
Per Patient
Pneumocystis carinii Trimethoprim-sulfamethoxazole
Dapsone
Aerosolized pentamidine
Atovaquone
160/800 mg q.d.
100 mg q.d.
300 mg q.m.
1500 mg q.d.
$135
$72
$1185
$11 627
Mycobacterium avium
complex
Clarithromycin
Azithromycin
Rifabutin
500 mg b.i.d.
1,200 mg q.w.
300 mg q.d.
$2843
$3862
$3352
Cytomegalovirus Ganciclovir (po)
Ganciclovir implant*
Ganciclovir (iv)
Foscarnet (iv)
Cidofovir (iv)
Fomivirsen (intravitreal)
Valganciclovir
1,000 mg t.i.d.
5 mg/kg q.d.
90–120 mg/kg q.d.
375 mg q.o.w.
1 vial every 4 wks
900 mg q.d.
$17 794
$5000
$13 093
$27 770–37 027
$20 904
$12 000
$21 582
Mycobacterium
tuberculosis
Isoniazid†
Rifampin
Pyrazinamide
300 mg q.d.
600 mg q.d.
1,500 mg q.d.
$23 (9 months)
$294 (2 months)
$194 (2 months)
Fungi Fluconazole
Itraconazole capsules
Itraconazole solution
Ketoconazole
200 mg q.d.
200 mg q.d.
200 mg q.d.
200 mg q.d.
$4603
$5340
$5673
$1230
Herpes simplex virus Acyclovir
Famciclovir
Valacyclovir
400 mg b.i.d.
500 mg b.i.d.
500 mg b.i.d.
$1384
$5311
$2538
Toxoplasma gondii Pyrimethamine
Leucovorin
Sulfadiazine
50 mg q.w.
25 mg q.w.
500 mg q.i.d.
$49
$988
$1490
Streptococcus pneumoniae 23-valent pneumococcal vaccine 0.5 ml im ´ 1 $13
Influenza virus Inactivted trivalent influenza vaccine 0.5 ml im ´ 1 $3
Hepatitis A virus Hepatitis A vaccine 1.0 ml im ´ 2 $124
Hepatitis B virus Recombinant hepatitis B 10–20 mg im ´ 3 $70
Bacterial infections G-CSF 300 mg t.i.w. $29 406
Varicella zoster virus VZIG 5 vials (6.25 ml) $562
ABBREVIATIONS: b.i.d. = twice daily; G-CSF = granulocyte-colony-stimulating factor; iv = intravenous; im = intramuscular; po = by
mouth; q.d. = daily; q.o.w. = every other week; q.w. = once a week; t.i.d. = three times daily; t.i.w. = three times a week;
VZIG = varicella zoster immune globulin.
*Implant generally lasts 6–9 months.
†Cost for 9 months of therapy.
Source: Medical Economics. Drug topics red book. Montvale, New Jersey: Medical Economics Inc., 2000
Table 9 Wholesale acquisition costs of agents recommended for the prevention of opportunistic infections in adults
infected with human immunodeficiency virusis probably prudent to continue PCP prophylaxis for life regardless of how high the CD4+ T
lymphocyte count rises as a consequence of HAART (CIII). Discontinuation of secondary
prophylaxis for patients is recommended (see above*).
Restarting secondary prophylaxis
Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to
< 200 cells/ml(AIII),orifPCPrecurred ataCD4+Tlymphocytecount> 200 cells/ml(CIII).
Special Considerations
Children
ChildrenborntoHIV-infected mothersshouldbeadministered prophylaxiswithTMP-SMZbeginningat
4–6 weeks ofage44 (AII). Prophylaxisshouldbediscontinuedfor children whoare subsequently foundnot
to be infected with HIV. HIV-infected children and children whose infection status remains unknown
shouldcontinuetoreceive prophylaxisforthefirst yearoflife.Theneedforsubsequentprophylaxisshould
be determined on the basis of age-specific CD4+ T lymphocyte count thresholds (Table 12) (AII). The
safety of discontinuing prophylaxis in HIV-infected children receiving HAART has not been studied
extensively. Children who have a history of PCP should be administered lifelong chemoprophylaxis to
prevent recurrence44 (AI).
Pregnant women
Chemoprophylaxis for PCP should be administered to pregnant women as is done for other adults and
adolescents (AIII). TMP-SMZ is the recommended prophylactic agent; dapsone is an alternative. Because
oftheoreticalconcernsregardingpossibleteratogenicityassociated withdrugexposures duringthefirst tri-
mester, providers may choose to withhold prophylaxis duringthe first trimester. In such cases, aerosolized
pentamidinemay beconsideredbecauseofitslackofsystemic absorptionandtheresultantlackofexposure
of the developing embryo to the drug (CIII).
TOXOPLASMIC ENCEPHALITIS
Prevention of exposure
HIV-infected persons should be tested for immunoglobulin G (IgG) antibody to Toxoplasma soon after
the diagnosis of HIV infection to detect latent infection with T. gondii (BIII).
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Age
Immunologic category
£ 12 months
cells/ml (%)
1–5 years
cells/ml (%)
6–12 years
cells/ml (%)
1.
2.
3.
No evidence of suppression
Evidence of moderate suppression
Severe suppression
‡ 1500 ( 25)
750–1499 (15–24)
< 750 (< 15)
‡ 1000 (‡ 25)
500–999 (15–24)
< 500 (< 15)
‡ 500 (‡ 25)
200–499 (15–24)
< 200 (< 15)
*Adapted from CDC. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age.
MMWR 1994;43(No. RR-12)
123
Table 10 Immunologic categories for human immunodeficiency virus-infected children based on age-specific CD4
+
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This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines as of November 1, 2000,
for children through age 18 years. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines
may be used whenever any components of the combination are indicated and the vaccine’s other components are not contraindicated.
Providers should consult the manufacturer’s package inserts for detailed recommendations.
1. Infants born to hepatitis B surface antigen (HBsAg)-negative mothers should receive the first dose of hepatitis B vaccine (Hep B)
at birth and no later than age 2 months. The second dose should be administered at least 1 month after the first dose. The third dose
should be administered at least 4 months after the first dose and at least 2 months after the second dose, but not before age 6 months.
Infants born to HBsAg-positive mothers should receive Hep B and 0.5 ml hepatitis B immune globulin (HBIG) within 12 hours of birth
at separate sites. The second dose is recommended at age 1–2 months and the third dose at age 6 months. Infants born to mothers
whose HBsAg status is unknown should receive Hep B within 12 hours of birth. Maternal blood should be drawn at delivery to
determine the mother’s HBsAg status; if the HBsAg test is positive, the infant should receive HIBG as soon as possible (no later than age
one week). All children and adolescents (through age 18 years) who have not been immunized against hepatitis B should begin the
series during any visit. Providers should make special efforts to immunize children who were born in or whose parents were born in areas
of the world where hepatitis B virus infection is moderately or highly endemic.
2. The fourth dose of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) may be administered as early as age 12 months,
provided 6 months have elapsed since the third dose and the child is unlikely to return at age 15–18 months. Tetanus and diphtheria toxoids
(Td) is recommended at age 11–12 years if at least 5 years have elapsed since the last dose of diphtheria and tetanus toxoids and pertussis
Table 11 Recommended immunization schedule for human immunodeficiency virus-infected children2001 USPHS/IDSA guidelines US Public Health Service
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vaccine (DTP), DTaP, or diphtheria and tetanus toxoids (DT). Subsequent routine Td boosters are recommended every 10 years.
3. Three Haemophilus influenzae type b (Hib) conjugate vaccines are licensed for infant use. If Hib conjugate vaccine (PRP-OMP)
(PedvaxHIB or ComVax [Merck]) is administered at ages 2 and 4 months, a dose at age 6 months is not required. Because clinical studies in
infants have demonstrated that using some combination products may induce a lower immune response to the Hib vaccine component,
DTaP/Hib combination products should not be used for primary immunization in infants at ages 2, 4 or 6 months unless approved by the
Food and Drug Administration for these ages.
4. An all-inactivated poliovirus vaccine (IPV) schedule is recommended for routine childhood polio vaccination in the United States. All
children should receive four doses of IPV at age 2 months, age 4 months, between ages 6 and 18 months, and between ages 4 and 6 years.
Oral poliovirus vaccine should not be administered to HIV infected persons or their household contacts.
5. Hepatitis A vaccine (Hep A) is recommended for use in selected states and/or regions, and for certain high-risk groups such as those
with Hepatitis B or Hepatitis C infection. Information is available from local public health authorities.
6. The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children age 2–59 months with HIV.
Children 2 years and older should also receive the 23 valent pneumococcal polysaccharide vaccine; a single revaccination with
the 23 valent vaccine should be offered to children after 3–5 years. Refer to the Advisory Committee on Immunization
Practices recommendations (80) on dosing intervals for children starting the vaccination schedule after 2 months of age.
7. MMR should not be administered to severely immunocompromisd (category 3) children. HIV infected children without severe
immunosuppression would routinely receive their first dose of MMR as soon as possible after reaching their first birthday. Consideration
should be given to administering the second dose of MMR as soon as 1 month (i.e., a minimum of 28 days) after the first dose rather than
waiting until school entry.
8. Varicella zoster virus vaccine, 0.5 ml, is given as a subcutaneous dose between 12 months and 12 years of age; a second
dose should be given 3 months later. The vaccine should be given only to asymptomatic, nonimmunosuppressed children.
9. For children aged 6 months to < 9 years who are receiving influenze vaccine for the first time, two injections given one
month apart are recommended. For specific recommendations, see: CDC, Prevention and Control of Influenza:
Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2001;50:RR-4. Inactivated split
influenza virus vaccine should be administered to all HIV infected children ‡ 6 months of age each year
Table 11 Continued
Preventive regimens
Pathogen Indication First choice Alternatives
I. Strongly recommended as standard of care
Pneumocystis carinii1 HIV-infected or
HIV-indeterminate, infants
aged 1–12 mo;
HIV-infected children aged
1–5 yr with CD4+ count
< 500/ml or CD4+
percentage < 15%;
HIV-infected children aged
6–12 yr with CD4+ count
< 200/ml or CD4+
percentage < 15%
Trimethoprim-sulfamethoxa
zole (TMP-SMZ),
150/750 mg/m2/d in 2
divided doses po t.i.w. on
consecutive days (All)
Acceptable alternative
dosage schedules: (AII)
Single dose po t.i.w. on
consecutive days;
2 divided doses po q.d.; 2
divided doses po t.i.w. on
alternate days
Dapsone (children aged ‡ 1
mo), 2 mg/kg (max 100 mg)
po q.d. or 4 mg/kg (max
200 mg) po q.w. (CII);
aerosolized pentamidine
(children aged ‡ 5 yr),
300 mg q.m. via Respirgard
IIÔ nebulizer (CIII);
atovaquone (children aged
1–3 mo. and > 24 mo.,
30 mg/kg po q.d., children
aged 4–24 mo., 45 mg/kg po
q.d.) (CII)
Mycobacterium tuberculosis2
Isoniazid-sensitive TST reaction, ‡ 5 mm or
prior positive TST result
without treatment; or
contact with any case of
active tuberculosis
regardless of TST result
Isoniazid 10–15 mg/kg (max
300 mg) po q.d. ´ 9 mo
(AII) or 20–30 mg/kg (max
900 mg po biw) ´ 9 months
(BII)
Rifampin, 10–20 mg/kg
(max 600 mg) po q.d.
plus pyrazinamide
15–20 mg/kg po q.d.
(max 2.0 g) ´ 2 mo (AI)
Table 12 Prophylaxis to prevent first episode of opportunistic disease in infants and children infected with human
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Isoniazid-resistant Same as above; high
probability of exposure to
isoniazid-resistant
tuberculosis
Rifampin, 10–20 mg/kg
(max 600 mg) po q.d.
plus pyrazinamide
15–20 mg/kg po q.d. ´ 2
mo (max 2 g) (AI)
Rifampin, 10–20 mg/kg (max
600 mg) po q.d. ´ 4–6 mo
(BIII)
Multidrug-(isoniazid and
rifampin) resistant
Same as above; high
probability of exposure to
multi-drug resistant
tuberculosis
Choice of drugs requires
consultation with public
health authorities and
depends on susceptibility
of isolate from source
patient
Mycobacterium avium
complex2
For children aged ‡ 6 yrs,
CD4+ count < 50/ml; aged
2–6 yrs CD4+ count
< 75/ml; aged 1–2 yrs,
CD4+ count < 500/ml; aged
< 1 yr, CD4+ count
< 750/ml
Clarithromycin 7.5 mg/kg
(max 500 mg) po b.i.d. (AII),
or azithromycin, 20 mg/kg
(max 1200 mg) po q.w. (AII)
Azithromycin, 5 mg/kg (max
250 mg) po q.d. (AII);
children aged ‡ 6 yrs,
rifabutin, 300 mg po q.d.
(BI)
Varicella zoster virus3 Significant exposure to
varicella or shingles with no
history of chickenpox or
shingles
Varicella zoster immune
globulin (VZIG), 1 vial
(1.25 ml)/10 kg (max 5 vials)
im, administered £ 96 hrs
after exposure, ideally
within 48 hrs (AII)
None
Vaccine-preventable
pathogens4
HIV exposure/infection Routine immunizations (see
Table 10)
None
II. Generally recommended
Toxoplasma gondii5 IgG antibody to Toxoplasma
and severe
immunosuppression
TMP-SMZ,
150/750 mg/m2/d in two
divided doses po q.d. (BIII)
Dapsone (children aged ‡ 1
mo), 2 mg/kg or 15 mg/m2
(max 25 mg) po q.d. plus
pyrimethamine, 1 mg/kg po
q.d. plus leucovorin, 5 mg
po every 3 days (BIII)
Atovaquone, (aged 1–3 mo.
and > 24 mo., 30 mg/kg po
q.d.; aged 14–24 mo.
45 mg/kg po q.d.) (CIII)
Varicella zoster virus3 HIV-infected children who
are asymptomatic and not
immunosuppressed
Varicella zoster vaccine (see
vaccine-preventable
pathogens section of this
table) (BII)
None
Table 12 Continued2001 USPHS/IDSA guidelines US Public Health Service
22 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY
Influenza virus All patients (annually, before
influenza season)
Inactivated split trivalent
influenza vaccine (see
vaccine-preventablesection
of this table) (BIII)
Oseltamivir (during
outbreaks of influenza A
or B) for children ‡ 13
years, 75 mg po q.d.
(CIII); Rimantadine or
amantadine (during
outbreaks of influenza A);
aged 1–9 yr, 5 mg/kg in 2
divided doses (max
150 mg/day) po q.d.; aged
‡ 10 yr, use adult doses
(CIII)
III. Not recommended for most children; indicated for use only in unusual circumstances
Invasive bacterial infections6 Hypogamma-globulinemia
(i.e., IgG < 400 mg/dl)
IVIG (400 mg/kg every 2–4
wks) (AI)
None
Cryptococcus neoformans Severe immunosuppression Fluconazole, 3–6 mg/kg po
q.d. (CII)
Itraconazole, 2–5 mg/kg po
every 12–24 h (CII)
Histoplasma capsulatum Severe immunosuppression,
endemic geographic area
Itraconazole, 2–5 mg/kg po
every 12–24 h (CIII)
None
Cytomegalovirus (CMV)7 CMV antibody positivity and
severe immunosuppression
Oral ganciclovir 30 mg/kg
po t.i.d. (CII)
None
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling
for the particular products or indications in question. Specifically, the terms ‘safe’ and ‘effective’ might not be synonymous with the
FDA-defined legal standards for product approval. The Respirgard IIÔ nebulizer is manufactured by Marquest, Englewood, Colorado.
Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendation and the quality of the evidence
supporting it (see Box, page 3).
ABBREVIATIONS: b.i.w. = twice a week; IVIG = intravenous immune globulin; q.d. = daily; q.m. = monthly; t.i.d. = three times a day;
t.i.w. = three times a week.
1Daily TMP-SMZ reduces the frequency of some bacterial infections. TMP-SMZ, dapsone-pyrimethamine, and possibly atovaquone (with or
without pyrimethamine) appear to protect against toxoplasmosis, although data have not been prospectively collected. When compared
with weekly dapsone, daily dapsone is associated with lower incidence of Pneumocystis carinii pneumonia (PCP) but higher hematologic
toxicity and mortality (McIntosh K, Cooper E, Xu J, et al. Toxicity and Efficacy of daily vs. weekly dapsone for prevention of
Pneumocystis carinii pneumonia in children infected with HIV. Ped Infect Dis J 1999;18:432–9).
The efficacy of parenteral pentamidine (e.g. 4 mg/kg q 2–4 wks) is controversial. Patients receiving therapy for toxoplasmosis with
sulfadiazine-pyrimethamine are protected against PCP and do not need TMP-SMZ.
2Significant drug interactions might occur between rifamycins (rifampin and rifabutin) and protease inhibitors and nonnucleoside reverse
transcriptase inhibitors. Consult a specialist.
3Children routinely being administered intravenous immune globulin (IVIG) should receive VZIG if the last dose of IVIG was administered
> 21 days before exposure.
4HIV-infected and HIV-exposed children should be immunized according to the childhood immunization schedule in this report (Table 10),
which has been adapted from the January–December 2001 schedule recommended for immunocompetent children by the Advisory
Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians. This
schedule differs from that for immunocompetent children in that both the conjugate pneumococcal vaccine (PCV-7) and the
pneumococcal polysaccharide vaccine (PPV-23) are recommended (BII) and vaccination against influenza (BIII) should be
offered. MMR should not be administered to severely immunocompromised children (DIII). Vaccination against varicella is indicated only
for asymptomatic nonimmunosuppressed children (BII). Once an HIV-exposed child is determined not to be HIV infected, the schedule for
immunocompetent children applies.
5Protection against toxoplasmosis is provided by the preferred antipneumocystis regimens and possibly by atovaquone. Atovaquone may be
used with or without pyrimethamine. Pyrimethamine alone probably provides little, if any, protection (for definition of severe
immunosuppression, see Table 9).
6Respiratory syncytial virus (RSV) IVIG (750 mg/kg), not monoclonal RSV antibody, may be substituted for IVIG during the RSV season to
provide broad antiinfective protection, if this product is available.
7Oral ganciclovir and perhaps valganciclovir results in reduced CMV shedding in CMV-infected children. Acyclovir is not protective against
CMV
Table 12 Continued2001 USPHS/IDSA guidelines US Public Health Service
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 23
Preventive Regimens
Pathogen Indication First Choice Alternatives
I. Recommended for life as standard of care
Pneumocystis carinii Prior P. carinii
pneumonia
TMP-SMZ, 150/750 mg/m2/d in
2 divided doses po t.i.w. on
consecutive days (AII)
Acceptable alternative schedules
for same dosage: (AII)
Single dose po t.i.w. on
consecutive days; 2 divided
doses po q.d.; 2 divided doses po
t.i.w. on alternate days
Dapsone (children aged ‡ 1 mo),
2 mg/kg (max 100 mg) po q.d. or
4 mg/kg (max 200 mg) po q.w.
(CII); aerosolized pentamidine
(children aged ‡ 5 yrs), 300 mg
q.m. via. Respirgard IIä
nebulizer (CIII); atovaquone
(aged 1–3 months and > 24 mo.,
30 mg/kg po q.d.; aged 4–24
mo., 45 mg/kg po q.d.) (CII)
Toxoplasma gondii1 Prior toxoplasmic
encephalitis
Sulfadiazine, 85–120 mg/kg/d in
2–4 divided doses po q.d. plus
pyrimethamine, 1 mg/kg or
15 mg/m2 (max 25 mg) po q.d.
plus leucovorin, 5 mg po every
3 days (AI)
Clindamycin, 20–30 mg/kg/d in
4 divided doses po q.d. plus
pyrimethamine, 1 mg/kg po q.d.
plus leucovorin, 5 mg po every
3 days (BI)
Mycobacterium avium
Complex2
Prior disease Clarithromycin, 7.5 mg/kg (max
500 mg) po b.i.d. (AII) plus
ethambutol, 15 mg/kg (max
900 mg) po q.d. (AII); with or
without rifabutin, 5 mg/kg (max
300 mg) po q.d. (CII)
Azithromycin, 5 mg/kg (max
250 mg) po q.d. (AII) plus
ethambutol, 15 mg/kg (max
900 mg) po q.d. (AII); with or
without rifabutin, 5 mg/kg (max
300 mg) po q.d. (CII)
Cryptococcus neoformans Documented disease Fluconazole, 3–6 mg/kg po q.d.
(AII)
Amphotericin B, 0.5–1.0 mg/kg
iv 1–3´/week (AI); itraconazole,
2–5 mg/kg po every 12–24h (BII)
Histoplasma capsulatum Documented disease Itraconazole, 2–5 mg/kg po
every 12–48h (AIII)
Amphotericin B, 1.0 mg/kg iv
q.w. (AIII)
Coccidioides immitis Documented disease Fluconazole, 6 mg/kg po q.d.
(AIII)
Amphotericin B, 1.0 mg/kg iv
q.w. (AIII); itraconazole,
2–5 mg/kg po every 12–48h
(AIII)
Cytomegalovirus Prior end-organ
disease
Ganciclovir, 5 mg/kg iv q.d.; or
foscarnet, 90–120 mg/kg iv q.d.
(AI)
(For retinitis) Ganciclovir
sustained-release implant every
6–9 mo. Plus ganciclovir,
30 mg/kg po t.i.d. (BIII)
Salmonella species
(non-typhi)3
Bacteremia TMP-SMZ, 150/750 mg/m2 in
2 divided doses po q.d. for
several months (CIII)
Antibiotic chemoprophylaxis
with another active agent (CIII)
Table 13 Prophylaxis to prevent recurrence of opportunistic disease (ater chemotherapy for acute disease) in
HIV-infected infants and childrenAll HIV-infected persons, but particularly those who lack IgG antibody to Toxoplasma, should be
counseled about the various sources of toxoplasmic infection. They should be advised not to eat raw or
undercooked meat, particularly undercooked lamb, beef, pork or venison (BIII). Specifically, lamb,
beef and pork should be cooked to an internal temperature of 165–170 F44; meat cooked until it is no
longer pink inside generally has an internaltemperature of 165–170F and therefore from a more practical
perspective, satisfies thisrequirement.HIV-infected personsshouldwashtheir handsaftercontactwithraw
meat andafter gardeningorothercontactwith soil; inaddition,theyshouldwash fruitsand vegetables well
before eating them raw (BIII). If the patient owns a cat, the litter box should be changed daily, preferably
by an HIV-negative, nonpregnant person; alternatively, the patient should wash the hands thoroughly
after changing the litter box (BIII). Patients should be encouraged to keep their cats inside and not to
adoptor handlestray cats (BIII). Cats shouldbefed only canned or dried commercial foodor well-cooked
table food, not raw or undercooked meats (BIII). Patients need not be advised to part with their cats or
to have their cats tested for toxoplasmosis (EII).
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II. Recommended only if subsequent episodes are frequent or severe
Invasive bacterial
Infections4
> 2 infections in
1-year period
TMP-SMZ, 150/750 mg/m2, in
2 divided doses po q.d. (BI); or
IVIG, 400 mg/kg every 2–4 wks.
(BI)
Antibiotic chemoprophylaxis
with another active agent (BIII)
Herpes simplex virus Frequent/severe
recurrences
Acyclovir, 80 mg/kg/d in 3–4
divided doses po q.d. (AII)
Candida (oropharyngeal) Frequent/severe
recurrences
Fluconazole, 3–6 mg/kg po q.d.
(CIII)
Candida (esophageal) Frequent/severe
recurrences
Fluconazole, 3–6 mg/kg po q.d.
(BIII)
Itraconazole solution, 5 mg/kg
po q.d. (CIII)
NOTES: Information included in these guidelines might not represent Food and Drug Administration (FDA) approval or approved labeling
for the particular products or indications in question. Specifically, the terms ‘safe’ and ‘effective’ might not be synonymous with the
FDA-defined legal standards for product approval. The Respirgard IIä nebulizer is manufactured by Marquest, Englewood, Colorado.
Letters and Roman numerals in parentheses after regimens indicate the strength of the recommendations and the quality of evidence
supporting it (see Box, page 3).
ABBREVIATIONS: IVIG = intravenous immune globulin; po = by mouth; q.d. = daily; q.m. = monthly; q.w. = weekly; t.i.d. = three times
a day; t.i.w. = three times a week; and TMP-SMZ = trimethoprim-sulfamethoxazole.
1Only pyrimethamine plus sulfadiazine confers protection against PCP as well as toxoplasmosis. Although the clindamycin plus
pyrimethamine regimen is recommended in adults, it has not been tested in children. However, these drugs are safe and are used for other
infections.
2Significant drug interactions might occur between rifabutin and protease inhibitors and nonnucleoside reverse transcriptase inhibitors.
Consult an expert.
3Drug should be determined by susceptibilities of the organism isolated. Alternatives to TMP-SMZ include ampicillin, chloramphenicol, or
ciprofloxacin. However, ciprofloxacin is not approved for use in persons aged < 18 years; therefore, it should be used in children with
caution and only if no alternatives exist.
4Antimicrobial prophylaxis should be chosen based on the microorganism and antibiotic sensitivities. TMP-SMZ, if used, should be
administered daily. Providers should be cautious about using antibiotics solely for this purpose because of the potential for development of
drug-resistant microorganisms. IVIG might not provide additional benefit to children receiving daily TMP-SMZ but may be considered for
children who have recurrent bacterial infections despite TMP-SMZ prophylaxis. Choice of antibiotic prophylaxis vs. IVIG should also involve
consideration of adherence, ease of intravenous access, and cost, if IVIG is used, respiratory syncytial virus (RSV) IVIG (750 mg/kg), not
monoclonal RSV antibody, may be substituted for IVIG during the RSV season to provide broad anti-infective protection, if this product is
available
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*Prevention of Disease
Initiation of primary prophylaxis
Toxoplasma-seropositive patients who have a CD4+ T lymphocyte count of less than 100/ml should be
administered prophylaxis against toxoplasmic encephalitis (TE) (AII)25. The double-strength tablet daily
dose of TMP-SMZ recommended as the preferred regimen for PCP prophylaxis appears to be effective
against TE as well and is therefore recommended (AII)25. If patients cannot tolerate TMP-SMZ, the
recommended alternative is dapsone-pyrimethamine, which is also effective against PCP (BI)29,30.
Atovaquone with or without pyrimethamine also may be considered (CIII). Prophylactic monotherapy
with dapsone, pyrimethamine, azithromycin, or clarithromycin cannot be recommended on the basis of
currentdata(DII).AerosolizedpentamidinedoesnotprotectagainstTEandisnotrecommended(EI)21,25.
Toxoplasma-seronegative persons who are not taking a PCP prophylactic regimen known to be active
against TE should be retested for IgG antibody to Toxoplasma when their CD4+ T lymphocyte count
declines below 100/ml to determine whether they have seroconverted and are therefore at risk for TE
(CIII). Patients who have seroconverted should be administered prophylaxis for TE as described above
(AII).
Discontinuation of primary prophylaxis
Prophylaxis against TE should be discontinued in adult and adolescent patients who have
responded to HAART with an increase in CD4+ T lymphocyte counts to > 200 cells/ml for at
least 3 months (AI).
Several observational studies37,41,47 and two randomized trials38,46 have shown that primary
prophylaxis can be discontinued with minimal risk of developing TE in patients who have
responded to HAART with an increase in CD4+ T lymphocyte count from < 200 cells/ml
to > 200 cells/ml for at least 3 months. In these studies, most patients were taking protease
inhibitor-containing regimens and the median CD4+ T lymphocyte count at the time prophy-
laxis was discontinued was > 300 cells/ml. At the time prophylaxis was discontinued, many
patients had sustained suppression of plasma HIV RNA levels below the detection limits of
available assays; the median follow up ranged from 7–22 months.
While patients with CD4+ T lymphocyte counts of < 100 cells/ml are at greatest risk for
developing TE, the risk of TE occurring when the CD4+ T lymphocyte count has increased
to 100–200 cells/ml has not been studied as rigorously as a rise to > 200 cells/ml. Thus, the
recommendation specifies discontinuation of prophylaxis after an increase to > 200 cells/ml.
Discontinuation of primary TE prophylaxis is recommended not only because prophylaxis
appears toaddvery littletodisease prevention for toxoplasmosis, butalsobecause discontinua-
tion of drug reduces pill burden, the potential for drug toxicity,drug interaction and selection
of drug resistant pathogens.
Restarting primary prophylaxis
Prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to
< 100–200 cells/ml (AIII).
Prevention of recurrence
Patientswhohavecompleted initialtherapy forTE shouldbeadministered lifelongsuppressive
therapy (secondary prophylaxis or CMT) (AI)48,49 unless immune reconstitution occurs as a
consequence of HAART (see below). The combination of pyrimethamine plus sulfadiazine
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who cannot tolerate sulfa drugs is pyrimethamine plus clindamycin (BI); however, only the
combination of pyrimethamine plus sulfadiazine appears toprovide protection against PCP as
well (AII).
Discontinuation of secondary prophylaxis (CMT)
Adult and adolescent patients receiving secondary prophylaxis (CMT) for TE appear to be
at low risk for recurrence of TE when they have successfully completed initial therapy for
TE, remain asymptomatic with respect to signs and symptoms of TE, and have a sustained
increase in their CD4+ T lymphocyte counts to > 200 cells/ml following HAART (e.g., 6
months)41,42,46. While the numbers of patients whohave been evaluated remain small and occa-
sional recurrences have been seen, based on these observations and on inference from more
extensivecumulativedatasuggesting thesafety ofdiscontinuationofsecondary prophylaxis for
other OIs during advanced HIV disease, it is reasonable toconsider discontinuation of CMT in
such patients (CIII). Some experts would obtain a magnetic resonance image of the brain as
part oftheirevaluationtodeterminewhetherornotdiscontinuationoftherapyisappropriate.
Restarting secondary prophylaxis
Secondary prophylaxis (CMT) should be reintroduced if the CD4+ T lymphocyte count
decreases to < 200 cells/ml (AIII).
Special considerations
Children
TMP-SMZ, when administered for PCP prophylaxis, also provides prophylaxis against toxoplasmosis.
Atovaquone might also provide protection (CIII). Children aged greater than 12 months who qualify for
PCP prophylaxis and who are receiving an agent other than TMP-SMZ or atovaquone should have sero-
logic testing for Toxoplasma antibody (BIII), because alternative drugs for PCP prophylaxis might not be
effective against Toxoplasma. Severely immunosuppressed children who are not receiving TMP-SMZ or
atovaquonewho are found to be seropositive for Toxoplasma should be administered prophylaxis for both
PCP and toxoplasmosis (i.e., dapsone plus pyrimethamine) (BIII).
Children with a history of toxoplasmosis should be administered lifelong prophylaxis to
prevent recurrence (AI). The safety of discontinuing primary or secondary prophylaxis in
HIV-infected children receiving HAART has not been studied extensively.
Pregnant Women
TMP-SMZcanbeadministered forprophylaxisagainst TEasdescribed forPCP(AIII).However, because
of the low incidence of TE during pregnancy and the possible risk associated with pyrimethamine treat-
ment, chemoprophylaxiswith pyrimethamine-containing regimens can reasonably be deferred until after
pregnancy (CIII). For prophylaxis against recurrent TE, the health-care provider and clinician should be
well informed about the benefit of lifelong therapy and the concerns about teratogenicity of
pyrimethamine. The above guidelines should be used when making decisions regarding secondary
prophylaxis for TE in pregnancy.
Inrarecases, HIV-infected pregnantwomenwhohaveserologicevidenceofremote toxoplasmicinfec-
tion have transmitted Toxoplasma to thefetusin utero.Pregnant HIV-infected women whohave evidence
ofprimary toxoplasmic infection oractive toxoplasmosis (includingTE)shouldbeevaluated and managed
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serologic evidence of infections with HIV and Toxoplasma should be evaluated for congenital
toxoplasmosis (BIII).
CRYPTOSPORIDIOSIS
Prevention of exposure
1. HIV-infected persons should be educated and counseled about the many ways that Cryptosporidium
can be transmitted (BIII). Modes of transmission include having direct contact with infected adults,
diaper-aged children and infected animals; drinking contaminated water; coming into contact with con-
taminated water during recreational activities and eating contaminated food.
2. HIV-infected persons should avoid contact with human and animal feces. They should be advised to
wash their hands after contact with human feces (e.g., diaper changing), after handling pets and after
gardening or other contactwith soil. HIV-infected persons should avoid sexual practices that might result
in oral exposure to feces (e.g., oral-anal contact) (BIII).
3. HIV-infected persons should be advised that newborn and very young pets might pose a small risk for
transmitting cryptosporidialinfection,buttheyshouldnotbeadvised to destroy orgive away healthy pets.
Personscontemplatingtheacquisition of a new petshouldavoid bringing anyanimal that hasdiarrhea into
their households,shouldavoid purchasingadogorcatagedless thansix months,and shouldnotadoptstray
pets. HIV-infected personswhowish to assume thesmall risk foracquiringa puppyorkitten aged less than
six monthsshouldrequestthattheir veterinarian examinetheanimal’sstoolforCryptosporidium beforethey
have contact with the animal (BIII).
4. HIV-infected persons should avoid exposure to calves and lambs and to premises where these animals
are raised (BII).
5. HIV-infected persons should not drink water directly from lakes or rivers (AIII).
6. Waterborne infection also might result from swallowing water during recreational activities.
HIV-infected persons should be aware that many lakes, rivers, salt-water beaches, and some swimming
pools, recreational water parks, and ornamental water fountains might be contaminated with human or
animal waste that containsCryptosporidium. They should avoid swimming in water that is likely to be con-
taminated and should avoid swallowing water while swimming or playing in recreational waters (BIII).
7. Several outbreaksof cryptosporidiosishave been linked to municipal water supplies. During outbreaks
orin othersituations in whicha community‘boil-water’ advisory is issued, boiling water for 1 minutewill
eliminate the risk for cryptosporidiosis (AI). Use of submicron personal-use water filters* (home/office
types) and/or bottled water** also might reduce the risk (CIII). The magnitude of the risk for acquiring
cryptosporidiosis from drinking water in a non-outbreak setting is uncertain, and current data are in-
adequate to recommend that all HIV-infected persons boil water or avoid drinking tap water in non-
outbreaksettings.However,HIV-infected personswhowish totakeindependentactiontoreducetherisk
for waterborne cryptosporidiosis may choose to take precautions similar to those recommended during
outbreaks.Suchdecisionsshouldbemadeinconjunctionwithhealth-careproviders.Personswhooptfora
personal-use filter or bottled water should be aware of the complexities involved in selecting appropriate
products, the lack of enforceable standards for the destruction or removal of oocysts, the cost of the
products, and the logistic difficulty of using these products consistently.
8. Patients who take precautions to avoid acquiring cryptosporidiosis from drinking water should be
advised thaticemade fromcontaminated tapwateralso canbeasourceofinfection(BII). Suchpersonsalso
should be aware that fountain beverages served in restaurants, bars, theaters and other places also might
posea risk because these beverages, as well astheice theycontain,aremade fromtapwater. Nationally dis-
tributed brands of bottled or canned carbonated soft drinks are safe to drink. Commercially packaged
non-carbonatedsoftdrinksandfruitjuices thatdonotrequirerefrigeration untilafter theyareopened(i.e.,
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frozen fruit juice concentrate are safe if they are reconstituted by the user with water from a safe source.
Fruit juices that must be kept refrigerated from the time they are processed to the time of consumption
might be either fresh (unpasteurized) or heat-treated (pasteurized); only those juices labeled as pasteurized
shouldbeconsideredfreeofrisk fromCryptosporidium.Otherpasterurizedbeverages andbeersalsoarecon-
sidered safe to drink (BII). No data are available concerning survival of Cryptosporidium oocysts in wine.
9. HIV-infected persons should avoid eating raw oysters because cryptosporidial oocysts can survive in
oysters for more than 2 months and have been found in oysters taken from some commercial oyster beds
(BIII). Cryptosporidium-infected patients should not work as food handlers, especially if the food to be
handled is intended to be eaten without cooking (BII). Because most food-borne outbreaks of
cryptosporidiosisare believed to have been caused by infected food handlers, more specific recommenda-
tions to avoid exposure to contaminated food cannot be made.
10. In a hospital,standard precautions(i.e., use ofglovesand handwashingafter removal ofgloves) should
be sufficient to prevent transmission of cryptosporidiosis from an infected patient to a susceptible
HIV-infected person (BII). However, because of the potential for fomite transmission, some experts
recommend that HIV-infected persons, especially those who are severely immunocompromised, should
not share a room with a patient with cryptosporidiosis (CIII).
Prevention of disease
11. Rifabutin or clarithromycin, when taken for Mycobacterium avium complex prophylaxis,
have been found to protect against cryptosporidiosis50,51. However, data are insufficient at
this time to warrant a recommendation for using these drugs as chemoprophylaxis for
cryptosporidiosis.
Prevention of recurrence
12. No drug regimens are known to be effective in preventing the recurrence of cryptosporidiosis.
Special considerations
Children
13. Atpresent, no dataindicatethatformula-preparationpractices for infantsshouldbealtered in an effort
to prevent cryptosporidiosis (CIII). However, in the event of a ‘boil water’ advisory, similar precautions
for the preparation of infant formula should be taken as for drinking water for adults (AII).
MICROSPORIDIOSIS
Prevention of exposure
1. Other than general attention to hand washing and other personal hygiene measures, no precautions to
reduce exposure can be recommended at this time.
Prevention of disease
2. No chemoprophylactic regimens are known to be effective in preventing microsporidiosis.
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3. No chemotherapeutic regimens are known to be effective in preventing the recurrence of
microsporidiosis.
TUBERCULOSIS
Prevention of exposure
1. HIV-infected personsshouldbeadvised thatcertainactivities andoccupationsmightincrease thelikeli-
hoodofexposuretotuberculosis(TB)(BIII). These includevolunteerworkoremploymentin health-care
facilities, correctionalinstitutionsand shelters forthehomeless, as well as inothersettings identifiedas high
risk by local health authorities.
Decisions about whether to continue with activities in these settings should be made in conjunction
with the health-care provider and should be based on factors such as the patient’s specific duties in the
workplace,theprevalence of TB in thecommunity and the degree to which precautionsare taken to pre-
vent the transmission of TB in the workplace (BIII). Whether the patient continues with such activities
might affect the frequency with which screening for TB needs to be conducted.
Prevention of disease
2. When HIV infection is first recognized, the patient should receive a tuberculin skin test (TST) by
administrationofintermediate-strength (5-TU)purifiedproteinderivative(PPD)bytheMantouxmethod
(AI). Routine evaluation for anergy is notrecommended. However, there are selected situations in which
anergy evaluation might assist in guiding individual decisions about preventive therapy52,53.
3. All HIV-infected persons who have a positive TST result (greater than orequal to 5 mm ofinduration)
shouldundergochestradiographyandclinical evaluation torule outactive TB.HIV-infected personswho
have symptoms suggestive of TB should promptly undergo chest radiography and clinical evaluation
regardless of their TST status (AII).
4. All HIV-infected persons, regardless of age, who have a positive TST result yet have no evidence of
active TB and no history of treatment for active or latent TB should be treated for latent TB infection.
Options include isoniazid daily (AII) or twice weekly (BII) for nine months; four months of therapy daily
with either rifampin (BIII) or rifabutin (CIII); or two months of therapy with either rifampin and
pyrazinamide (BI) or rifabutin and pyrazinamide (CIII)52–54. There have been reports of fatal and severe
liver injuryassociatedwiththetreatmentoflatentTBinfectioninHIV-uninfectedpersonstreated withthe
two-month regimen of daily rifampin and pyrazinamide; therefore it may be prudent to use regimens that
do not contain pyrazinamide in HIV-infected persons whose completion of treatment can be assured55.
Because HIV-infected persons are at risk for peripheral neuropathy, those receiving isoniazid should also
receive pyridoxine (BIII). A decision to use a regimen containing either rifampin or rifabutin should be
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*Only filters capable of removing particles 1 mm in diameter should be considered. Filters that provide the greatest assurance of oocyst
removal include those that operate by reverse osmosis, those labeled as absolute 1 mm filters, and those labeled as meeting NSF
(National Sanitation Foundation) standard no. 53 for cyst removal. The nominal 1 mm filter rating is not standardized, and many filters
in this category might not be capable of removing 99% of oocysts. For a list of filters certified as meeting NSF standards, consult the
International Consumer Line at 800-673-8010 or http://www.nsf.org/notice/crypto.html
**Sources of bottled water (e.g., wells, springs, municipal tap-water supplies, rivers and lakes) and methods for its disinfection differ;
therefore, all brands should not be presumed to be free of cryptosporidial oocysts. Water from wells and springs is much less likely to be
contaminated by oocysts than water from rivers or lakes. Treatment of bottled water by distillation or reverse osmosis ensures oocyst
removal. Water passed through an absolute 1 mm filter or a filter labeled as meeting NSF standard no. 53 for cyst removal before
bottling will provide nearly the same level of protection. Use of nominal 1 mm filters by bottlers as the only barrier to Cryptosporidia
might not result in the removal of 99% of oocysts. For more information, the International BottledWater Association can be contacted
at 703-683-5213 or at http://bottled water.orgmade after careful consideration of potential drug interactions, especially those related to protease inhibi-
tors and nonnucleoside reverse transcriptase inhibitors (see Special Considerations/Drug Interactions).
Directly observed therapy should be used with intermittent dosing regimens (AI) and when otherwise
operationally feasible (BIII)53.
5. HIV-infected persons who are close contacts of persons who have infectious TB should be treated for
latentTBinfection–regardless oftheir TSTresults, ageorpriorcoursesoftreatment–afterthediagnosisof
active TBhas been excluded (AII)52–54. In addition to household contacts, such persons might also include
contactsinthesame drug-treatmentorhealth-carefacility,co-workersandothercontactsif transmission of
TB is demonstrated.
6. For personsexposedto isoniazid- and/orrifampin-resistant TB,thedecision to use chemoprophylactic
antimycobacterial agents other than isoniazid alone, rifampin or rifabutin alone, rifampin plus
pyrazinamide or rifabutin plus pyrazinamide should be based on the relative risk for exposure to resistant
organisms and should be made in consultation with public health authorities (AII).
7. TST-negative, HIV-infected persons from risk groups or geographic areas with a high prevalence of
Mycobacteriumtuberculosisinfectionmightbeatincreased risk forprimaryorreactivation tuberculosis.How-
ever, the efficacy of treatment in this group has not been demonstrated. Decisions concerning the use of
chemoprophylaxis in these situations must be considered individually.
8. Althoughthe reliability of the TST might diminish as the CD4+ T lymphocytecount declines, annual
repeat testing should be considered for HIV-infected persons who are TST-negative on initial evaluation
and who belong to populations in which there is a substantial risk for exposure to M. tuberculosis (BIII).
Clinicians should consider repeating the TST for persons whose initial skin test was negative
and whose immune function has improved in response to HAART (i.e., those whose CD4+
T lymphocyte count has increased to greater than 200 cells/ml) (BIII)52. In addition to confirming
TB infection, TST conversion in an HIV-infected person should alert health-care providers to the possi-
bility of recent M. tuberculosis transmission and should prompt notification of public health officials for
investigation to identify a possible source case.
9. The administration of bacille Calmette-Guerin (BCG) vaccine to HIV-infected persons is contra-
indicated because of its potential to cause disseminated disease (EII).
Prevention of recurrence
10. Chronicsuppressive therapy for a patient whohas successfully completed a recommended regimen of
treatment for tuberculosis is not necessary (DII).
Special Considerations
Drug interactions
11. Rifampin can induce metabolism of all the protease inhibitors and nonnucleoside reverse
transcriptase inhibitors. This can result in more rapid drug clearance and possibly sub-
therapeutic drug concentrations of most of these antiretroviral agents. Rifampin should not be
co-administered with the following protease inhibitors and nonnucleoside reverse trans-
criptase inhibitors: amprenavir, indinavir, lopinavir/ritonavir, nelfinavir, saquinavir and
delavirdine53. However, it may be used with ritonavir, ritonavir plus saquinavir, efavirenz and
possibly with nevirapine. Rifabutin is an acceptable alternative to rifampin but should not be
used with the protease inhibitor hard-gel saquinavir or delavirdine; caution is advised if the
drug is coadministered with soft-gel saquinavir, because data are sparse. Rifabutin can be
administered atone-half theusual daily dose, i.e., reduce from 300 mg to150 mg per day, with
indinavir, nelfinavir or amprenavir or with one-fourth the usual dose, i.e., 150 mg every other
day or three times a week, with ritonavir, ritonavir plus saquinavir, or lopinavir/ritonavir.
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indinavir should be increased from 800 mg every 8 h to 1000 mg every 8 h. Pharmacokinetic
data suggest that rifabutin at an increased dose can be administered with efavirenz; doses of
450–600 mg per day have been suggested54. However, little information is available about
appropriate dosing if a protease inhibitor is used concurrently with efavirenz and rifabutin;
with such a combination the rifabutin dose might need to be reduced. Rifabutin can be used
without dose adjustment with nevirapine.
Children
12. Infants born to HIV-infected mothers should have a TST (5-TU PPD) at or before the age of 9–12
months and should be retested at least once a year (AIII). HIV-infected children living in householdswith
TST-positive persons should be evaluated for TB (AIII); children exposed to a person who has active TB
should be administered preventive therapy after active TB has been excluded, regardless of their TST
results (AII).
Pregnant women
13. Chemoprophylaxis for TB is recommended during pregnancy for HIV-infected patients who have
either a positive TST or a history of exposure to active TB, after active TB has been excluded (AIII). A
chest radiographshouldbeobtainedbeforetreatment and appropriateabdominal/pelvic lead apronshields
shouldbeusedtominimize radiationexposuretotheembryo/fetus.WhenanHIV-infectedpersonhasnot
been exposed to drug-resistant TB, isoniazid daily or twice weekly is the prophylactic regimen of choice.
Because of concerns regarding possible teratogenicity associated with drug exposures during the first
trimester, providers may choose to initiate prophylaxis after the first trimester. Preventive therapy with
isoniazid should be accompanied by pyridoxine to reduce the risk for neurotoxicity. Experience with
rifampin or rifabutin during pregnancy is more limited, but anecdotal experience with rifampin has not
been associated with adverse pregnancyoutcomes.Pyrazinamide should generally beavoided, particularly
in the first trimester because of lack of information concerning fetal effects.
DISSEMINATED INFECTION WITH MYCOBACTERIUM AVIUM COMPLEX
Prevention of exposure
1. Organisms of the M. avium complex (MAC) are common in environmental sources such as food and
water.Currentinformationdoesnotsupportspecificrecommendationsregardingavoidanceofexposure.
Prevention of disease
Initiation of primary prophylaxis
2. Adults and adolescents who have HIV infection shouldreceive chemoprophylaxisagainst disseminated
MAC disease if they have a CD4+ T lymphocyte count of less than 50 cells/ml (AI)56. Clarithromycin57,58
or azithromycin59 are the preferred prophylactic agents (AI). The combination of clarithromycin and
rifabutin is no more effective than clarithromycin alone for chemoprophylaxis and is associated with a
higher rate of adverse effects than either drugalone; this combinationshouldnotbe used (EI)59. Thecom-
binationof azithromycin withrifabutin ismoreeffective than azithromycin alone;however, theadditional
cost, increased occurrence of adverse effects, potential for drug interactions and absence of a difference in
survival when compared with azithromycin alonedo notwarrant a routine recommendation for this regi-
men (CI)59.Inadditiontotheirpreventive activityforMACdisease,clarithromycinandazithromycineach
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tolerated, rifabutin is an alternative prophylacticagentforMAC disease althoughrifabutin-associated drug
interactions make this agent difficult to use (BI)54. Tolerance, cost and drug interactions are among the
issues that should be considered in decisions regarding the choice of prophylacticagents for MAC disease.
Particular attention to interactions with antiretroviral protease inhibitors and nonnucleoside reverse
transcriptase inhibitors is warranted (see Special Considerations/Drug Interactions). Before prophylaxis is
initiated, disseminated MAC disease should be ruled out by clinical assessment, which might include
obtaining a blood culture for MAC if warranted. Because treatment with rifabutin could result in the
development of resistance to rifampin in persons who have active TB, active TB should also be excluded
before rifabutin is used for prophylaxis.
3. Although the detection of MAC organisms in the respiratory or gastrointestinal tract might predict
the development of disseminated MAC infection,no data are available on the efficacy of prophylaxiswith
clarithromycin, azithromycin, rifabutin or other drugsin patientswith MAC organisms at these sites and a
negative blood culture.Therefore, routinescreening of respiratory or gastrointestinal specimens for MAC
cannot be recommended (DIII).
Discontinuation of primary prophylaxis
4. PrimaryMACprophylaxisshouldbediscontinued inadultandadolescent patientswhohave
responded to HAART with an increase in CD4+ T lymphocyte count to > 100 cells/ml for at
least three months (AI). Two large randomized, placebo controlled trials and observational
data have shown that such patients can discontinue primary prophylaxis with minimal risk of
developing MAC37,60–62.Discontinuationofprimary prophylaxisinpatientsmeetingthecriteria
above is recommended not only because prophylaxis appears to add very little to disease pre-
vention for MAC or for bacterial infections, but also because discontinuation of drug reduces
pill burden, thepotential for drug toxicity,drug interactions, selection of drug resistant patho-
gens and cost.
Restarting primary prophylaxis
5. Primary prophylaxis should be reintroduced if the CD4+ T lymphocyte count decreases to
< 50–100 cells/ml (AIII).
Prevention of recurrence
6. Adult and adolescent patients with disseminated MAC should receive lifelong therapy (i.e.,
secondary prophylaxis or CMT) (AII), unless immune reconstitution occurs as a consequence
of HAART (see guideline 7 below). Unless good clinical or laboratory evidence of macrolide
resistance exists, the use of a macrolide (clarithromycin or, alternatively, azithromycin) is
recommended in combination withethambutol (AII)withor withoutrifabutin (CI)63,64.Treat-
ment of MAC disease withclarithromycin in a dose of 1000 mg twice a day is associated with a
highermortalityratethanhasbeen observed withclarithromycinadministered at500 mgtwice
a day; thus, the higher dose should not be used (EI)65,66. Clofazimine has been associated with
adverse clinical outcomes in the treatment of MAC disease and should not be used (DII)66.
Discontinuation of secondary prophylaxis (CMT)
7. Patients appear to be at low risk for recurrence of MAC when they have completed a
course of at least 12 months of treatment for MAC, remain asymptomatic withrespect toMAC
2001 USPHS/IDSA guidelines US Public Health Service
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 33signs and symptoms, and have a sustained increase , e.g., six months, in their CD4+ T lympho-
cytecounts to> 100 cells/ml following HAART. While the numbers of patients who have been
evaluated remain small, and recurrences could occur41,42,68–70, based on these observations and
on inference from more extensive data suggesting the safety of discontinuation of secondary
prophylaxis for other OIs during advanced HIV disease, it may be reasonable to consider dis-
continuation of CMT in such patients (CIII). Some experts would obtain a blood culture for
MAC, even in asymptomatic patients, prior to discontinuation of therapy, to substantiate that
disease is no longer active.
Restarting secondary prophylaxis
8. Secondary prophylaxisshouldbereintroduced iftheCD4+Tlymphocytecount decreases to
< 100 cells/ml (AIII).
Special considerations
Drug interactions
9. Rifabutin should not be administered to patients receiving certain protease inhibitors and
nonnucleoside reverse transcriptase inhibitors because the complex interactions have been
incompletely studied and the clinical implications of those interactions are unclear16,54 (see
Special Considerations: Drug interactions in theTuberculosis section, above). Protease inhibi-
tors may increase clarithromycin levels, but no recommendation to adjust the dose of either
clarithromycin or protease inhibitors can be made on the basis of existing data. Efavirenz can
induce metabolism of clarithromycin. This may result in reduced serum concentration of
clarithromycin but increased concentration of 14-OH clarithromycin, an active metabolite of
clarithromycin. Althoughthe clinical significance of this interaction is not known, the efficacy
of clarithromycin in MAC prophylaxis could be reduced because of this interaction. Azithro-
mycinpharmacokinetics are notaffected bythecytochromeP450system;azithromycincanbe
used safely in the presence of protease inhibitors and/or nonnucleoside reverse transcriptase
inhibitors without concerns of drug interactions.
Children
10. HIV-infected children aged less than 13 years who have advanced immunosuppression also can
developdisseminated MACinfectionsandprophylaxisshouldbeofferedtohigh-riskchildrenaccordingto
the following CD4+ T lymphocyte thresholds: children aged greater than or equal to six years, less than
50 cells/ml; children aged 2–6 years, less than 75 cells/ml; children aged 1–2 years, less than 500 cells/ml;
and children aged less than 12 months, less than 750 cells/ml (AII). For the same reasons that
clarithromycin and azithromycin are the preferred prophylacticagents for adults, they should also be con-
sidered for children (AII); oral suspensions of both agents are commercially available in the United States.
No liquid formulation of rifabutin suitable for pediatric use is commercially available in the United States.
Children with a history of disseminated MAC should be administered lifelong prophylaxis to prevent
recurrence (AII). The safety of discontinuing MAC prophylaxis in children whose CD4+ T lymphocyte
counts have increased in response to HAART has not been studied.
Pregnant women
11. Chemoprophylaxis for MAC disease should be administered to pregnant women as is done for other
adults and adolescents (AIII). However, because of general concernsaboutadministering drugs duringthe
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Animalstudiesandanecdotalevidenceofsafetyinhumanssuggestthatoftheavailableagents,azithromycin
is the drugof choice (BIII)71. Experience with rifabutin is limited. Clarithromycin has been demonstrated
to be a teratogen in animals and should be used with caution during pregnancy72. For secondary prophy-
laxis (CMT), azithromycin plus ethambutol are the preferred drugs (BIII)70.
BACTERIAL RESPIRATORY INFECTIONS
Prevention of exposure
1. BecauseStreptococcuspneumoniaeandHaemophilusinfluenzaearecommoninthecommunity,noeffective
way exists to reduce exposure to these bacteria.
Prevention of disease
2. Adults and adolescents who have a CD4+ T lymphocyte count of greater than or equal to
200 cells/ml should be administered a single dose of 23-valent polysaccharide pneumococcal
vaccine if they have not received this vaccine during the previous five years (BII)73–77. One
randomized placebo-controlled trial of pneumococcal vaccine in Africa paradoxically found
an increase in pneumonia among vaccinated subjects78.However, several observational studies
in the United States have not identified increased risk associated with vaccination and have
identified benefit in this group73–77. Most experts believe that the potential benefit of pneumo-
coccal vaccination in the United States outweighs the risk. Immunization should also be con-
sidered for patients with CD4+ T lymphocyte counts < 200 cells/ml, although there is no
clinical evidence for efficacy (CIII). Revaccination may be considered for patients who were
initiallyimmunized when theirCD4+ T lymphocytecount was < 200 cells/ml and whose CD4+
count has increased to > 200 cells/ml in response to HAART (CIII). The recommendation to
vaccinate is increasingly pertinent because of the increasing incidence of invasive infections
with drug-resistant (including TMP-SMZ-, macrolide- and beta-lactam-resistant) strains of
S. pneumoniae.
3. The duration of the protective effect of primary pneumococcal vaccination is unknown. Periodic
revaccination may be considered; an interval of five years has been recommended for persons notinfected
with HIV and also might be appropriate for persons infected with HIV (CIII)76. There is, however, no
evidence for clinical benefit from revaccination.
4. TheincidenceofH. influenzaetypeB infection in adultsis low.Therefore,H. influenzaetypeB vaccine
is not generally recommended for adult use (DIII).
5. TMP-SMZ, when administered daily for PCP prophylaxis, reduces the frequency of bacterial respira-
toryinfections.Thisshouldbeconsideredintheselection ofanagentforPCPprophylaxis(AII).However,
indiscriminate use of this drug (when not indicated for PCP prophylaxis or other specific reasons) might
promotethe development of TMP-SMZ-resistant organisms. Thus, TMP-SMZ shouldnotbeprescribed
solely to prevent bacterial respiratory infection (DIII). Similarly, clarithromycin administered daily and
azithromycinadministered weeklyforMACprophylaxismightbeeffectiveinpreventingbacterialrespira-
tory infections; this should be considered in the selection of an agent for prophylaxis against MAC disease
(BII). However, these drugs should not be prescribed solely for preventing bacterial respiratory infection
(DIII).
6. An absoluteneutrophilcountthatis depressed becauseofHIV disease ordrugtherapyis associated with
an increased risk for bacterial infections, including pneumonia.To reduce therisk for such bacterial infec-
tions, providers may consider taking steps to reverse neutropenia, either by stopping myelosuppressive
drugs (CII) or by administering granulocyte-colony-stimulating factor (G-CSF) (CII).
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7. Some clinicians may administer antibiotic chemoprophylaxis to HIV-infected patients who have very
frequent recurrences of serious bacterial respiratory infections (CIII). TMP-SMZ, administered for PCP
prophylaxis and clarithromycin or azithromycin, administered for MAC prophylaxis, are appropriate for
drug-sensitive organisms. However, providers should be cautious about using antibiotics solely for pre-
venting the recurrence of serious bacterial respiratory infections because of the potential development of
drug-resistant microorganisms and drug toxicity.
Special considerations
Children
8. HIV infected children, less than five years old should be administered H. influenzae type B
vaccine (AII)and pneumococcal conjugate vaccine77–81 (BII)in accordance with the guidelines
of the Advisory Committee on Immunization Practices74,76,79 and the American Academy of
Pediatrics80. Children aged greater than two years should also receive the 23-valent poly-
saccharide pneumococcal vaccine (BII). Revaccination with a second dose of the 23 valent
polysaccharide pneumococcal vaccine should generally be offered after 3–5 years to children
aged less than or equal to ten years and after five years to children aged greater than ten
years (BIII).
9. To prevent serious bacterial infections in HIV-infected children who have hypogammaglobulinemia
(IgG less than 400 mg/dl), clinicians should use intravenous (i.v.) immunoglobulin (IVIG) (AI). Respira-
torysyncytialvirus(RSV)IVIG(750 mg/kg),notmonoclonalRSVantibody,maybesubstitutedforIVIG
during the RSV season to provide broad anti-infective protection, if RSV IVIG is available.
10. To prevent recurrence of serious bacterial respiratory infections, antibiotic chemoprophylaxismay be
considered (BI). However, providers should be cautious about using antibiotics solely for this purpose
because of thepotentialdevelopmentof drug-resistant microorganisms and drugtoxicity.Theadministra-
tion of IVIG should also be considered for HIV-infected children who have recurrent serious bacterial
infections, although such treatment might not provide additional benefit to children who are being
administered daily TMP-SMZ. However, IVIG may be considered for children who have recurrent
serious bacterial infections despite receiving TMP-SMZ or other antimicrobials (CIII)82.
Pregnant women
11. Pneumococcal vaccination is recommended during pregnancy for HIV-infected patients who have
notbeenvaccinatedduringthepreviousfiveyears(BIII). Amongnonpregnantadults,vaccinationhasbeen
associated with a transient burst of HIV replication. Whetherthetransient viremia can increase therisk for
perinatal HIV transmission is unknown. Because of this concern, when feasible, vaccination may be
deferred until after HAART has been initiated to prevent perinatal HIV transmission (CIII).
BACTERIAL ENTERIC INFECTIONS
Prevention of exposure
Food
1. Health-care providers shouldadvise HIV-infected personsnottoeat raw orundercookedeggs (includ-
ing foods that might contain raw eggs [e.g., some preparations of hollandaise sauce, Caesar and certain
other salad dressings, some mayonnaises, uncooked cookie and cake batter, egg nog]); raw or
undercooked poultry, meat, seafood (especially raw shellfish); unpasteurized dairy products; un-
pasteurized fruit juices; and raw seed sprouts (e.g., alfalfa sprouts, mung bean sprouts). Poultry
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ture of 180°F for poultry and 165°F for red meats). If a thermometer is not used, the risk of ill-
ness isdecreased byconsuming poultryandmeat thathavenotraceofpinkcolor.Colorchange
of the meat (e.g., absence of pink) does not always correlate with internal temperature. (BIII).
Produce should be washed thoroughly before being eaten (BIII).
2. Health-care providers should advise HIV-infected persons to avoid cross-contamination of foods.
Uncookedmeats, (including hot dogs)and theirjuicesshouldnotcome intocontactwithotherfoods.
Hands, cuttingboards,counters,knives,and otherutensilsshouldbewashedthoroughlyafter contactwith
uncooked foods (BIII).
3. Health-care providers should advise HIV-infected persons that, although the incidence of
listeriosisislow,itisaserious disease thatoccurswithunusually highfrequency among severely
immunosuppressed HIV-infected persons. An immunosuppressed, HIV-infected person who
wishes to reduce the risk of acquiring listeriosis as much as possible may choose to do the
following (CIII): a) avoid soft cheeses (e.g., feta, Brie, Camembert, blue-veined and
Mexican-style cheese suchas queso fresco). Hard, processed and cream cheese (including slices
and spreads), cottage cheese or yogurt need not be avoided; b) cook leftover foods or
ready-to-eat foods (e.g., hotdogs)untilsteaming hotbefore eating; c)avoidfoods from delica-
tessencounters (e.g.,prepared salads, meats,cheeses) orheat/reheat thesefoods untilsteaming
before eating; d) avoid refrigerated pates and other meat spreads, or heat/reheat these foods
until steaming. Canned or shelf-stable pate and meat spreads need not be avoided and e) avoid
raw or unpasteurized milk (including goat’s milk) or milk-products, or foods which contain
unpasteurized milk or milk-products. (CIII).
Pets
4. When obtaining a new pet, HIV-infected persons should avoid animals aged less than six months,
especially those that have diarrhea (BIII).
5. HIV-infected persons should avoid contact with animals that have diarrhea (BIII). HIV-infected pet
owners should seek veterinary care for animals with diarrheal illness, and a fecal sample from such animals
should be examined for Cryptosporidium, Salmonella, and Campylobacter.
6. HIV-infected persons should wash their hands after handlingpets (especially before eating) and should
avoid contact with pets’ feces (BIII).
7. HIV-infected persons should avoid contact with reptiles (e.g., snakes, lizards, iguanas and turtles) as
well as chicks and ducklings because of the risk for salmonellosis (BIII).
Travel
8. Therisk forfood-borneandwaterborneinfectionsamongimmunosuppressed,HIV-infected personsis
magnified during travel to developing countries. Persons who travel to such countries should avoid foods
and beverages that might be contaminated, particularly raw fruits and vegetables, raw or undercooked
seafood or meat, tap water, ice made with tap water, unpasteurized milk and dairy products, and items
sold by street vendors (AII). Foods and beverages that are generally safe include steaming-hot foods, fruits
thatarepeeled bythetraveler, bottled(especially carbonated)beverages, hotcoffeeandtea,beer,wine,and
water brought to a rolling boil for 1 minute (AII). Treatment of water with iodine or chlorine might not
be as effective as boiling but can be used when boiling is not practical (BIII).
2001 USPHS/IDSA guidelines US Public Health Service
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 37Prevention of disease
9. Prophylacticantimicrobial agentsarenotgenerally recommendedfortravelers (DIII).Theeffectiveness
of these agents depends on local antimicrobial-resistance patterns of gastrointestinal pathogens, which are
seldom known. Moreover, these agents can elicit adverse reactions and can promote the emergence of
resistant organisms. However, for HIV-infected travelers, antimicrobial prophylaxis may be considered,
depending on the level of immunosuppression and the region and duration of travel (CIII). The use of
fluoroquinolones such as ciprofloxacin (500 mg per day) can be considered when prophylaxis is deemed
necessary (CIII). As an alternative (e.g., for children, pregnant women, and persons already taking
TMP-SMZ for PCP prophylaxis), TMP-SMZ might offer some protection against traveler’s diarrhea
(BIII). The risk of toxicity should be considered before treatment with TMP-SMZ is initiated solely
because of travel.
10. Antimicrobial agents such as fluoroquinolones should be given to patients before their departure, to
be taken empirically (e.g., 500 mg of ciprofloxacin twice a day for 3–7 days) should significant traveler’s
diarrhea develop (BIII). Fluoroquinolones should be avoided for children aged less than 18 years and
pregnant women, and alternative antibiotics should be considered (BIII). Travelers should consult a
physician if their diarrhea is severe and doesnotrespondto empirical therapy, if their stools contain blood,
if fever is accompanied by shaking chills, or if dehydration develops. Antiperistaltic agents (e.g.,
loperamide) can be used to treat mild diarrhea. However, the use of these drugs should be discontinued
if symptoms persist beyond48 h.Moreover, these agents shouldnotbe administered to patients whohave
a high fever or who have blood in the stool (AII).
11. Some experts recommend that HIV-infected persons whohave Salmonellagastroenteritis be adminis-
tered antimicrobial therapy to prevent extraintestinal spread of the pathogen. However, no controlled
study has demonstrated a beneficial effect of such treatment, and some studies of immunocompetent
personshavesuggested thatantimicrobial therapycanlengthenthesheddingperiod.Thefluoroquinolones
– primarily ciprofloxacin (750 mg twice a day for 14 days) – can be used when antimicrobial therapy is
chosen (CIII).
Prevention of recurrence
12. HIV-infected persons who have Salmonella septicemia require long-term therapy (i.e., secondary
prophylaxis or CMT) to prevent recurrence. Fluoroquinolones, primarily ciprofloxacin, are usually the
drugs of choice for susceptible organisms (BII).
13. HouseholdcontactsofHIV-infected personswhohavesalmonellosisorshigellosis shouldbeevaluated
for persistent asymptomatic carriage of Salmonella or Shigella so that strict hygienic measures and/or
antimicrobial therapy can be instituted and recurrent transmission to the HIV-infected person can be
prevented (CIII).
Special considerations
Children
14. Like HIV-infected adults, HIV-infected children should wash their hands after handling pets (espe-
ciallybeforeeating)andshouldavoidcontactwithpets’feces.Handwashingshouldbesupervised (BIII).
15. HIV-exposed infants aged less than three months and all HIV-infected children who have severe
immunosuppression should be administered treatment for Salmonella gastroenteritis to prevent extra-
intestinal spreadofthepathogen(CIII). ChoicesofantibioticsincludeTMP-SMZ,ampicillin, cefotaxime,
ceftriaxone or chloramphenicol;fluoroquinolonesshould be used with caution and only if no alternatives
exist.
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prevent recurrence (CIII). TMP-SMZ is the drugof choice; ampicillin or chloramphenicolcan be used if
theorganismissusceptible.Fluoroquinolonesshouldbeusedwithcautionandonlyifnoalternative exists.
17. Antiperistaltic drugs are not recommended for children (DIII).
Pregnant women
18. Because bothpregnancyand HIV infection conferarisk forlisteriosis, pregnantHIV-infected women
should heed recommendations regarding listeriosis (BII).
19. Because extraintestinal spread of Salmonella during pregnancy might lead to infection of the placenta
and amniotic fluid and result in pregnancy loss similar to that seen with Listeria monocytogenes, pregnant
women with Salmonella gastroenteritis should receive treatment (BIII). Choices for treatment include
ampicillin, cefotaxime, ceftriaxone, or TMP-SMZ. Fluoroquinolones should be avoided.
20. Fluoroquinolones should not be used during pregnancy. TMP-SMZ might offer some protection
against traveler’s diarrhea.
BARTONELLOSIS
Prevention of exposure
1. HIV-infected persons,particularlythosewhoareseverely immunosuppressed,areat unusuallyhighrisk
fordevelopingrelatively severe disease duetoinfectionwithBartonella,whichcanbetransmitted fromcats.
These personsshouldconsiderthepotentialrisks ofcatownership(CIII). Personswhoacquirea catshould
adopt or purchase an animal aged greater than one year that is in good health (BII).
2. Although declawing is not generally advised, HIV-infected persons should avoid rough play with cats
and situations in which scratches are likely (BII). Any cat-associated wound should be washed promptly
(CIII). Cats should not be allowed to lick open wounds or cuts of HIV-infected persons (BIII).
3. Care of cats should include flea control (CIII).
4. No evidence indicates any benefits to cats or their owners from routine culture or serologic testing of
the pet for Bartonella infection (DII).
Prevention of disease
5. No data support chemoprophylaxis for Bartonella-associated disease (CIII).
Prevention of recurrence
6. Relapse or reinfection with Bartonellahas sometimes followeda course of primary treatment. Although
no firm recommendation can be made regarding prophylaxis in this situation, long-term suppression of
infection with erythromycin or doxycycline should be considered (CIII).
Special considerations
Children
7. The risks of cat ownership for HIV-infected children who are severely immunocompromised should
be discussed with parents and caretakers (CIII).
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8. Iflong-termsuppression of Bartonella infection is required,erythromycin shouldbeused. Tetracycline
should not be used during pregnancy.
CANDIDIASIS
Prevention of exposure
1. Candida organisms are common on mucosal surfaces and skin. No measures are available to reduce
exposure to these fungi.
Prevention of disease
2. Data from prospective controlled trials indicate that fluconazole can reduce the risk for mucosal
(oropharyngeal, esophageal and vaginal) candidiasis and cryptococcosis as well in patients with advanced
HIV disease76–78. However, routine primary prophylaxis is not recommended because of the effectiveness
oftherapyforacutedisease, thelowmortality associated withmucosal candidiasis,thepotentialforresistant
Candida organisms to develop, the possibility of drug interactions, and the cost of prophylaxis (DIII).
Prevention of recurrence
3. Many experts do not recommend chronic prophylaxis of recurrent oropharyngeal or vulvovaginal
candidiasisforthesame reasons thattheydonotrecommendprimaryprophylaxis.However,ifrecurrences
are frequent or severe, providers may consider administering an oral azole (fluconazole [CI]83–85 or
itraconazole solution [CI]). Other factors that influence choices about such therapy include the impact of
the recurrences on the patient’s well-being and quality of life, the need for prophylaxis for other fungal
infections, cost, toxicities, drug interactions, and the potential to induce drug resistance among Candida
and other fungi. Prolonged use of systemically absorbed azoles, particularly in patients with low CD4+
Tlymphocytecounts(i.e., less than100 cells/ml),increases theriskforthedevelopmentofazoleresistance.
4. Adults or adolescents who have a history of documented esophageal candidiasis, particularly multiple
episodes, should be considered candidates for chronic suppressive therapy. Fluconazole at a dose of
100–200 mg daily is appropriate (BI). However, the potential development of azole resistance should be
taken into account when long-term azoles are considered.
Special considerations
Children
5. Primary prophylaxis of candidiasis in HIV-infected infants is not indicated (DIII).
6. Suppressive therapy with systemic azoles should be considered for infants who have severe recurrent
mucocutaneous candidiasis (CIII) and particularly for those who have esophageal candidiasis (BIII).
Pregnant women
7. Experience is limited with the use of systemic antifungal drugs during human pregnancy. Four cases of
infants born with craniofacial and skeletal abnormalities following prolonged in utero exposure to
fluconazole have been reported86,87. In addition, itraconazole is embryotoxic and teratogenic in animal
systems88. Thesesame potentialrisksofteratogenicityare presumed toapply toothersystemically absorbed
azole antifungals, such as ketoconazole. Therefore, chemoprophylaxis against oropharyngeal, esophageal,
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and azoles should be discontinued for HIV-infected women who become pregnant (DIII). Effective birth
control measures should be recommended to all HIV-infected women on azole therapy for candidiasis
(AIII).
CRYPTOCOCCOSIS
Prevention of exposure
1. HIV-infected persons cannot completely avoid exposure to Cryptococcus neoformans. No evidence
existsthatexposuretopigeondroppingsisassociated withanincreasedrisk foracquiringcryptococcosis.
Prevention of disease
2. Routine testing of asymptomatic persons for serum cryptococcalantigen is notrecommended because
of the low probability that the results will affect clinical decisions (DIII).
3. Prospective controlled trials indicate that fluconazole and itraconazole can reduce the frequency of
cryptococcaldisease amongpatientswhohave advancedHIV disease. However,most experts recommend
that antifungal prophylaxis not be used routinely to prevent cryptococcosis because of the relative
infrequencyofcryptococcaldisease, thelack ofsurvival benefitsassociated withprophylaxis,thepossibility
of drug interactions, the potential development of antifungal drug resistance, and cost. The need for
prophylaxis or suppressive therapy for other fungal infections (e.g., candidiasis, histoplasmosis, or
coccidioidomycosis) should be considered in making decisions about prophylaxis for cryptococcosis. If
used, fluconazole at doses of 100–200 mg daily is reasonable for patients whose CD4+ T lymphocyte
counts are less than 50 cells/ml (CI)83.
Prevention of recurrence
4. Patientswhohavecompletedinitialtherapyforcryptococcosisshouldbeadministered lifelongsuppres-
sive treatment, (i.e., secondary prophylaxis or CMT) (AI) unless immune reconstitution occurs as a
consequence of HAART (see recommendation 5 below). Fluconazole is superior to
itraconazole in preventing relapse of cryptococcal disease and is the preferred drug (AI)89–91.
Discontinuation of secondary prophylaxis (CMT)
5. Adultand adolescent patientsappear tobe atlowriskfor recurrence ofcryptococcosiswhen
they have successfully completed a course of initial therapy for cryptococcosis, remain asymp-
tomatic with respect to signs and symptoms of cryptococcosis, and have a sustained increase
(e.g., six months)intheirCD4+Tlymphocytecountsto> 100–200 cells/mlfollowing HAART.
The numbers of patients who have been evaluated remain small92,93. Based on these observa-
tions and on inference from more extensive data suggesting the safety of discontinuation of
secondary prophylaxis for other OIs during advanced HIV disease and whilerecurrences could
occur it may be reasonable to consider discontinuation of CMT in such patients (CIII). Some
experts would perform a lumbar puncture to determine if the CSF is culture negative before
stopping therapy even if patients have been asymptomatic; other experts do not believe this is
necessary.
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6. Maintenance therapy should be reinitiated if the CD4+ T lymphocyte count decreases to
100–200 cells/ml (AIII).
Special considerations
Children
7. No dataexist on which to base specific recommendationsfor children, but lifelong suppressive therapy
with fluconazole after an episode of cryptococcosis is appropriate (AIII).
Pregnant women
8. Prophylaxis with fluconazole or itraconazole should not be initiated during pregnancy because of the
low incidence of cryptococcal disease, the lack of a recommendation for primary prophylaxis against
cryptococcosis in nonpregnant adults, and potential teratogenic effects of these drugs during pregnancy
(DIII)86,87. For patients who conceive while being administered primary prophylaxis and who elect to
continuetheir pregnancy,prophylaxisshouldbediscontinued.The occurrenceofcraniofacial and skeletal
abnormalities in infants following prolonged in utero exposure to fluconazole should be considered when
assessing the therapeutic options for HIV-infected women who become pregnant and are receiving
secondary prophylaxis (CMT) for cryptococcosis86,87. If a woman meets the criteria for discontinua-
tion of secondary prophylaxis as discussed above, strong consideration should be given to dis-
continuing therapy during pregnancy as long as the CD4+ T lymphocyte could remains above
100–200 cells/ml. Forpatientsrequiring therapy,amphotericin B may bepreferred, especially duringthe
first trimester. Effective birth control measures should be recommended to all HIV-infected women on
azole therapy for cryptococcosis (AIII).
HISTOPLASMOSIS
Prevention of exposure
1. Although HIV-infected persons living in or visiting histoplasmosis-endemic areas cannot completely
avoid exposure to Histoplasma capsulatum, those whose CD4+ T lymphocyte counts are less than
200 cells/ml should avoid activities known to be associated with increased risk (e.g., creating dust when
workingwithsurfacesoil;cleaningchickencoopsthatareheavilycontaminatedwithdroppings;disturbing
soil beneath bird-roosting sites; cleaning, remodeling or demolishing old buildings; and exploring caves)
(CIII).
Prevention of disease
2. Routine skin testing with histoplasmin and serologic testing for antibody or antigen in
histoplasmosis-endemic areas are not predictive of disease and should not be performed (DII).
3. Datafroma prospectiverandomized controlledtrialindicatethatitraconazolecan reducethefrequency
of histoplasmosis among patients who have advanced HIV infection and who live in H. capsulatum-
endemic areas94. However, no survival benefit was observed among persons receiving itraconazole.
Prophylaxis with itraconazole may be considered in patients with CD4+ T lymphocyte counts less
than 100 cells/ml who are at especially high risk because of occupational exposure or who live in a
community with a hyperendemic rate of histoplasmosis (greater than or equal to ten cases per 100
patient-years) (CI).
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4. Patients who complete initial therapy for histoplasmosis should be administered lifelong suppressive
treatment (i.e., secondary prophylaxis or CMT) with itraconazole (200 mg twice a day) (AI)94.
Discontinuation of secondary prophylaxis (CMT)
5. Although patients receiving secondary prophylaxis (CMT) might be at low risk for recurrence of
systemic mycosis when their CD4+ T lymphocyte counts increase to greater than 100 cells/ml, in
responsetoHAART,thenumbersofpatientswhohavebeenevaluated areinsufficienttowarrantarecom-
mendation to discontinue prophylaxis.
Special considerations
Children
6. Because primary histoplasmosis can lead to disseminated infection in children, a reasonable option
is to administer lifelong suppressive therapy after an acute episode of the disease (AIII).
Pregnant women
7. Because of the embryotoxicity and teratogenicity of itraconazole in animal systems, primary prophy-
laxis against histoplasmosis shouldnotbeofferedduringpregnancy(DIII)81.Thesedataaswellastheobser-
vation of craniofacial and skeletal abnormalities in infants following prolonged in utero exposure to
fluconazole86,87shouldbeconsidered when assessing theneed for CMT in HIV-infected pregnantwomen
withhistoplasmosis. Forsuchpatients,therapywithamphotericinBmaybepreferred,especially duringthe
first trimester. For women receiving HAARTwitha sustained risein CD4+ T lymphocytecounts
above 100 cells/ml, discontinuation of azole prophylaxis, especially during the first trimester,
should be considered. Effective birth control measures should be recommended to all HIV-infected
women on azole therapy for histoplasmosis (AIII).
COCCIDIOIDOMYCOSIS
Prevention of exposure
1. Although HIV-infected persons living in or visiting areas in which coccidioidomycosis is endemic
cannot completely avoid exposure to Coccidioides immitis, they should, when possible, avoid activities
associated with increased risk (e.g., those involving extensive exposure to disturbed native soil, for
example, at building excavation sites or during dust storms) (CIII).
Prevention of disease
2. Routine skin testing with coccidioidin (spherulin) in coccidioidomycosis-endemic areas is notpredic-
tive ofdisease and shouldnotbe performed (DII). Within the endemic area, a positive serologic test might
indicate an increased risk for active infection; however, routine testing does not appear to be useful and
should not be performed (DIII).
3. Primary prophylaxis for HIV-infected persons who live in coccidioidomycosis-endemic areas is not
routinely recommended.
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4. Patients who complete initial therapy for coccidioidomycosis should be administered lifelong
suppressive therapy (i.e., secondary prophylaxis or CMT) (AII) using either 400 mg of fluconazole by
moutheach day or200 mg ofitraconazoletwicea day96. Patients with meningeal disease require consulta-
tion with an expert.
Discontinuation of secondary prophylaxis (CMT)
5. Although patients receiving secondary prophylaxis (CMT) might be at low risk for recurrence of
systemic mycosis when their CD4+ T lymphocyte counts increase to greater than 100 cells/ml, in
responsetoHAART,thenumbersofpatientswhohavebeenevaluated areinsufficienttowarrantarecom-
mendation to discontinue prophylaxis.
Special considerations
Children
6. Although no specific data are available regarding coccidioidomycosis in HIV-infected children, a
reasonableoptionistoadministerlifelongsuppressivetherapyafteranacuteepisodeofthedisease (AIII).
Pregnant women
7. The potential teratogenicity of fluconazole86,87 and itraconazole81 should be considered when assessing
the therapeutic options for HIV-infected women who become pregnant while receiving CMT for
coccidioidomycosis. For such patients, therapy with amphotericin B may be preferred, especially during
the first trimester. For women receiving HAART with a sustained rise in CD4+ T lymphocyte
counts above 100 cells/ml, discontinuation of azole prophylaxis, especially during the first
trimester, should be considered. Effective birth control measures should be recommended for all
HIV-infected women on azole therapy for coccidioidomycosis (AIII).
CYTOMEGALOVIRUS DISEASE
Prevention of exposure
1. HIV-infected persons who belong to risk groups with relatively low rates of seropositivity for
cytomegalovirus (CMV) and who therefore cannot be presumed to be seropositive should be tested for
antibody to CMV (BIII). These groups include patients who have not had male homosexual contact or
used injection drugs.
2. HIV-infected adolescents and adults should be advised that CMV is shed in semen, cervical secretions
and saliva and thatlatex condomsmust always beused duringsexual contactto reducetherisk forexposure
to CMV and to other sexually transmitted pathogens (AII).
3. HIV-infected adults and adolescents who are child-care providers or parents of children in child-care
facilities should be informed that they are at increased risk for acquiring CMV infection (BI). Similarly,
parentsand other caretakers of HIV-infected children shouldbeadvised of the increased risk to children at
these centers (BIII). The risk for acquiring CMV infection can be diminished by good hygienic practices
such as hand washing (AII).
4. HIV-exposed infants and HIV-infected children, adolescents, and adults who are seronegative for
CMV and require blood transfusion should be administered only CMV antibody-negative or leuko-
cyte-reduced cellular blood products in nonemergency situations (BIII).
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5. Prophylaxis with oral ganciclovir may be considered for HIV-infected adults and adolescents who are
CMV seropositive and who have a CD4+ T lymphocyte count of less than 50 cells/ml (CI)97,98.
Ganciclovir-induced neutropenia, anemia, conflicting reports of efficacy, lack of proven survival benefit,
the risk for developing ganciclovir-resistant CMV and cost are among the issues that should be considered
whendecidingwhethertoinstituteprophylaxisinindividualpatients.Acyclovirisnoteffectiveinprevent-
ing CMV disease, and valacyclovir is notrecommended because ofan unexplainedtrend toward increased
deathsamong personswith AIDSwhowere administered valacyclovir forCMVprophylaxis99. Therefore,
neither acyclovir nor valacyclovir should be used for this purpose (EI). The most important method for
preventing severe CMV disease is recognition of the early manifestations of the disease. Early recognition
of CMV retinitis is most likely when the patient has been educated on this topic. Patients should be made
aware of the significance of increased floaters in the eye and should be advised to assess their visual acuity
regularly by using simple techniques such as reading newsprint (BIII). Regular funduscopicexaminations
performed by an ophthalmologist are recommended by some experts for patients with low (e.g., less than
50 cells/ml) CD4+ T lymphocyte counts (CIII).
Prevention of recurrence
6. CMV disease is not cured with courses of the currently available antiviral agents (e.g., ganciclovir,
foscarnet,cidofoviror fomivirsen). Followinginductiontherapy,secondary prophylaxis(CMT) is recom-
mended for life (AI), unless there is immune reconstitution as a consequence of HAART (see
recommendation 7 below). Regimens demonstrated to beeffective forchronicsuppression in random-
ized, controlled clinical trials include parenteral or oral ganciclovir, parenteral foscarnet, combined
parenteral ganciclovir and foscarnet,parenteralcidofovir,and(forretinitisonly)gancicloviradministration
via intraocular implant or repetitive intravitreous injections of fomivirsen (AI)100–108. Oral
valganciclovir has been approved by the FDA for both acute induction therapy and for main-
tenance therapy although much of the data have not been published. Repetitive intra-
vitreousinjections ofganciclovir, foscarnet andcidofovir have been reported tobe effective for
secondary prophylaxis of CMV retinitis in uncontrolled case series109,110. Intraoculartherapy alone
does not provide protection to the contralateral eye or to other organ systems and typically is combined
with oral ganciclovir100. The choice of a CMT for patients treated for CMV disease should be made in
consultationwithanexpert.Forpatientswithretinitis, thisdecisionshouldbemadeinconsultationwithan
ophthalmologistandshouldtakeintoconsiderationtheanatomiclocationoftheretinallesion,vision inthe
contralateral eye, the immunologic and virologic status of the patient, and the patient’s response to
HAART (BIII).
Discontinuation of secondary prophylaxis (CMT)
7. Several case series have reported that maintenance therapy can be discontinued safely in
adultandadolescent patientswithCMVretinitiswhoseCD4+Tlymphocytecountshaveshown
a sustained (e.g., six months) increase to > 100–150 cells/ml in response to HAART112–116.
These patients have remained disease-free for greater than 30–95 weeks, whereas in the
pre-HAART era, retinitis typically reactivated within 6–8 weeks after stopping CMV therapy.
Plasma HIV RNA levels were variable in these patients, suggesting that the CD4+ T lympho-
cyte count is the primary determinant of immune recovery to CMV. Discontinuation of
prophylaxisshouldbeconsidered inpatients withasustained, (e.g.,6months)increase inCD4+
T lymphocyte count to > 100–150 cells/ml in response toHAART (BII).Such decisions should
be made in consultation with an ophthalmologist and should take into account such factors as
magnitude and duration of CD4+ T lymphocyte increase, anatomic location of the retinal
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(BII).All patients whohave had anti-CMV maintenance therapy discontinued should continue
to undergo regular ophthalmologic monitoring for early detection of CMV relapse (as well as
for immune reconstitution uveitis) (AIII). CMV viral load or other markers of CMV infection,
e.g., antigenemia or viral DNA tests are not well standardized; their role in predicting relapse
remains to be defined117–118. Relapses have been reported rarely in patients with CD4+
T lymphocyte count > 100–150 cells/ml119.
Restarting secondary prophylaxis
8. Relapse of CMV retinitis occurs in patients whose anti-CMV maintenance therapy
has been discontinued and whose CD4+ T lymphocyte count has decreased to 50 cells/ml109.
Therefore, reinstitution of secondary prophylaxis should be reinstituted when the CD4+
T-lymphocyte count has decreased to 100–150 cells/ml (AIII). Relapse has been reported in
patients whose CD4+ T lymphocyte counts are higher then 100 cells/ml, but such reports are
rare to date119.
Special considerations
Children
9. Some experts recommend obtaining a CMV urine culture on all HIV-infected (or exposed) infants at
birth or at an early postnatal visit to identify those infants with congenital CMV infection (CIII). In addi-
tion, beginning at one year of age, CMV antibody testing on an annual basis may be considered for
CMV-seronegative (and culture-negative) HIV-infected infants and children who are severely immuno-
suppressed (Table 10) (CIII). Annualtesting will allow identification ofchildren whohave acquired CMV
infection and might benefit from screening for retinitis.
10. HIV-infected children who are CMV-infected and severely immunosuppressed might benefit from a
dilated retinal examination performed by an ophthalmologist every 4–6 months (CIII). In addition, older
children should be counseled to be aware of floaters in the eye, similar to the recommendation for adults
(BIII).
11. Oral ganciclovir results in reduced CMV shedding in CMV-infected children and may be considered
for primary prophylaxis against CMV disease in CMV-infected children who are severely immuno-
suppressed (e.g., CD4+ T lymphocyte count less than 50 cells/ml) (CII).
12. Patients with a history of CMV disease should be administered lifelong prophlyaxis to
prevent recurrence (AII). For children with CMV disease, no data are available to guide decisions
concerning discontinuation of secondary prophylaxis (CMT) when the CD4+ T lymphocyte count has
increased in response to HAART.
Pregnant women
13. Indications for prophylaxis are the same for pregnant women as for non-pregnant women.
The choice of agents to be used in pregnancy should be individualized after consultation with experts.
HERPES SIMPLEX VIRUS DISEASE
Prevention of exposure
1. HIV-infected personsshoulduselatex condomsduringeveryactofsexualintercoursetoreducetherisk
forexposureto herpessimplex virus (HSV) and to othersexually transmitted pathogens(AII). Theyshould
specifically avoid sexual contact when herpetic lesions (genital or orolabial) are evident (AII).
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2. Antiviral prophylaxisafter exposureto HSV, orto preventinitial episodesof HSV disease in individuals
with latent infection is not recommended (DIII).
Prevention of recurrence
3. Because episodes of HSV disease can be treated successfully, chronic therapy with acyclovir is not
required after lesions resolve. However, persons who have frequentor severe recurrences can be adminis-
tered daily suppressive therapy with oral acyclovir or oral famciclovir (AI)120–121. Valacyclovir also is an
option(CIII). Foscarnet or cidofovir i.v. can be used to treat infection due to acyclovir-resistant isolates of
HSV, which are routinely resistant to ganciclovir as well (AII).
Special considerations
Children
4. Therecommendationsforpreventinginitial disease and recurrenceamong adultsand adolescents apply
to children as well.
Pregnant women
5. Oral acyclovir prophylaxis during late pregnancy is a controversial strategy recommended by some
experts to prevent neonatal herpes transmission. However, such prophylaxis is not routinely recom-
mended. For patients who have frequent, severe recurrences of genital HSV disease, acyclovir prophylaxis
might be indicated (BIII). No pattern of adverse pregnancy outcomes has been reported after acyclovir
exposures122.
VARICELLA-ZOSTER VIRUS DISEASE
Prevention of exposure
1. HIV-infected children and adults who are susceptible to varicella-zoster virus (VZV) (i.e., those who
have no history of chickenpoxor shingles or are seronegative for VZV) should avoid exposure to persons
with chickenpox or shingles (AII). Household contacts (especially children) of susceptible HIV-infected
persons should be vaccinated against VZV if they have no history of chickenpox and are seronegative for
HIV, so that they will not transmit VZV to their susceptible HIV-infected contacts (BIII).
Prevention of disease
2. Very little dataregarding thesafety and efficacyofvaricella vaccine inHIV-infected adultsare available,
andnorecommendationforits use canbemadeforthispopulation.(SeeSpecial Considerations/Children,
below).
3. For the prophylaxisof chickenpox,HIV-infected children and adults whoare susceptible to VZV (i.e.,
those who have no history of chickenpox or shingles or who have no detectable antibody against VZV)
should be administered varicella zoster immune globulin (VZIG) as soon as possible but within 96 h after
close contactwith a patient whohas chickenpoxor shingles (AIII). Data are lacking on theeffectiveness of
acyclovir for preventing chickenpox in susceptible HIV-infected children or adults.
4. No preventive measures are currently available for shingles.
Prevention of recurrence
5. No drug has been proven to prevent the recurrence of shingles in HIV-infected persons.
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Children
6. HIV-infected children who are asymptomatic and not immunosuppressed (i.e., in immunologic
category1, Table10) shouldreceive live attenuated varicella vaccine at 12–15 monthsof age or later (BII).
Varicella vaccine should not be administered to other HIV-infected children because of the potential for
disseminated viral infection (EIII).
Pregnant women
7. VZIG is recommended for VZV-susceptible, HIV-infected pregnant women within 96 h after
exposure to VZV (AIII). If oral acyclovir is used, VZV serology should be performed so that the drug can
be discontinued if the patient is seropositive for VZV (BIII).
HUMAN HERPESVIRUS 8 INFECTION (KAPOSI’S SARCOMA-ASSOCIATED
HERPES VIRUS)
Prevention of exposure
1. Persons co-infected with HIV and HHV-8 are at risk for developing Kaposi’s sarcoma (KS)
and, thereisevidence thatprogression toKSmay beaccelerated inindividualswhoseroconvert
toHHV-8 after being infected with HIV. Thus it isimportant toprevent acquisition of HHV-8
infections in those already infected with HIV123–125. The three major routes of HHV-8 trans-
missionappear tobe oral (thevirusinfectsoralepithelial cells, andinfectionhasbeen associated
with deep kissing), via semen (HHV-8 is less frequently detected in semen than in saliva), and
through blood via needle sharing126–128. Patients should be counseled that deep kissing and
sexual intercourse with individuals who have high risk of being infected with HHV-8, e.g.,
persons who have KS or who are infected with HIV, may lead to acquisition of the agent that
causes KS (CIII).Althoughtheefficacy of condom use for preventing HHV-8 exposure has not
been established, HIV-infected persons should use latex condoms during every act of sexual
intercourse toreduce exposure tosexually transmittedpathogens (AII).HIV-infected injection
drug users should be counseled to not share drug injection equipment, even if both users are
already HIV-infected, because of the chance of becoming infected with HHV-8 or other
bloodborne pathogens (BIII).
Prevention of disease
2. Because clinical use of routine serologic testing to identify HHV-8 infection has not been established,
no recommendation for serologic testing can be made at this time.
3. Lower rates of KS have been observed among AIDS patients treated with ganciclovir or foscarnet for
CMV retinitis99. HHV-8 replication in vitro is inhibited by ganciclovir, foscarnet, and cidofovir. How-
ever, because the efficacy and clinical use of these drugs in preventing KS have not been established, no
recommendation can be made concerning the use of these or other drugs to prevent KS in individuals
coinfected with HIV and HHV-8.
4. Potent antiretroviral drug combinations that suppress HIV replication reduce the frequency of KS in
HIV-infected persons129 and should be considered for all persons who qualify for such therapy (BII).
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5. Effective suppression of HIV replication with antiretroviral drugs in HIV-infected patients with KS
might prevent KS progression or the development of new lesions and should be considered for all persons
with KS (BII).
Special considerations
Children
6. In parts of the world where HHV-8 is endemic, mother-to-child transmission of HHV-8 has been
reported and130–133horizontaltransmission among youngchildren,possiblyvia saliva occurs.However, no
recommendations are currently available for preventing HHV-8 transmission from child to child.
HUMAN PAPILLOMAVIRUS INFECTION
Prevention of exposure
1. HIV-infected personsshoulduselatex condomsduringeveryactofsexualintercoursetoreducetherisk
forexposuretosexuallytransmitted pathogens(AII),althoughlittleevidenceexists tosuggestthatcondoms
reduce the risk for infection with human papillomavirus (HPV).
Prevention of disease
HPV-associated genital epithelial cancers in HIV-infected women
2. After a complete history of previous cervical disease has been obtained, HIV-infected women should
have a pelvic examination and a Pap smear. In accordance with the recommendation of the Agency for
Health Care PolicyandResearch, thePap smear shouldbeobtainedtwicein thefirst year after diagnosisof
HIV infection and, if the results are normal, annually thereafter (AII).
3. If the results of thePap smear are abnormal,care shouldbe provided according to theInterim Guidelines
forManagementof AbnormalCervicalCytology publishedbya National Cancer InstituteConsensusPaneland
briefly summarized in Recommendations 4–8, which follow134.
4. For patients whose Pap smears are interpreted as atypical squamous cells of undetermined significance
(ASCUS), several management optionsareavailable; thechoicedependsinpartonwhethertheinterpreta-
tion of ASCUS is qualified by a statement indicating that a neoplastic process is suspected. Follow-up by
Pap tests without colposcopy is acceptable, particularly when the diagnosis of ASCUS is not qualified
further or the cytopathologist suspects a reactive process. In such situations, Pap tests should be repeated
every 4–6 months for 2 years until three consecutive smears have been negative. If a second report of
ASCUS occursinthe2-yearfollow-upperiod,thepatientshouldbeconsideredforcolposcopicevaluation
(BIII).
5. Women who have a diagnosis of unqualified ASCUS associated with severe inflammation should be
evaluated for an infectious process. If specific infections are identified, reevaluation should be performed
after appropriate treatment, preferably after 2–3 months (BIII).
6. IfthediagnosisofASCUS isqualifiedbyastatement indicatingthataneoplasticprocessissuspected,the
patient should be managed as if a low-grade squamous intraepithelial lesion (LSIL) were present (see
recommendation 7) (BIII). If a patient who has a diagnosis of ASCUS is at high risk (i.e., previous positive
Pap tests or poor adherence to follow-up), the option of colposcopy should be considered (BIII).
7. Several management options are available for patients who have LSIL. Follow up with Pap tests every
4–6 months is used by many clinicians and is currently used in countries outside the United States as an
established methodofmanagement.Patientsmanagedinthiswaymustbecarefullyselected andconsidered
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indicated (BIII). Colposcopy and directed biopsy of any abnormal area on the ectocervix constitute
another appropriate option (BIII).
8. Women who have cytologic diagnosis of high-grade squamous intraepithelial lesions (HSILs) or
squamous cell carcinoma should undergo colposcopy and directed biopsy (AII).
9. No data are available to suggest that these guidelines to prevent cervical disease should be modified for
women on HAART.
HPV-associated anal intraepithelial neoplasia and anal cancer in HIV-infected homosexuals
and in women
10. Evidence from several studies shows that HPV-positive homosexuals and HPV infected women are
at increased risk for anal HSILs and might be at increased risk for anal cancer. In view of this evidence,
coupled with a recent cost-effectiveness analysis projecting that screening and treatment for anal HSILs
provide clinical benefits comparable to other measures to prevent OIs in HIV-infected persons131, anal
cytology screening of HIV-infected homosexuals and women might become a useful preventive measure
inthenear future.However, furtherstudies ofscreening and treatment programsforanal HSILs needtobe
carried out before recommendations for routine anal cytology screening can be made.
Prevention of recurrence
11. The risks for recurrence of squamous intraepithelial lesions and cervical cancer after conventional
therapy are increased among HIV-infected women. The prevention of illness associated with recurrence
dependsoncarefulfollow-upofpatientsafter treatment.Patientsshouldbemonitored withfrequentcyto-
logic screening and, when indicated, with colposcopic examination for recurrent lesions (AI)134,144.
12. In one recent study of HIV-infected women treated for HSILs using standard therapy, low-dose
intravaginal 5-fluorouracil (2 g twice a week for six months) reduced the short-term risk for recurrence
and possibly the grade of recurrence136. However, clinical experience with this therapy is too limited to
provide a recommendation for routine use.
Special considerations
Pregnant women
13. Use of intravaginal 5-fluorouracil to prevent recurrent dysplasia is not recommended during
pregnancy.
HEPATITIS C VIRUS INFECTION
Prevention of exposure
1. The chief route of hepatitis C virus (HCV) transmission in the United States is injection drug use.
Because injection drug use is a complex behavior, clinicians should assess the individual’s readiness to
changethispracticeandencourageeffortstoprovidepatienteducationandsupportdirectedatrecovery.
Patients who inject drugs should be advised137–139
(a) to stop using injection drugs (AIII);
(b) to enter and complete a substance-abuse treatment program, including a relapse prevention program
(AIII).
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￿ to never reuse or share syringes, needles, rinse water or drug preparation equipment; if, nonetheless,
injection equipment that has been used by other persons is shared, to first clean the equipment with
bleach and water as is recommended for prevention of HIV;
￿ to use only sterile syringes obtained from a reliable source (e.g., pharmacies or syringe exchange
programs);
￿ tousesterile (e.g.,boiled)water topreparedrugs;if notpossible,touseclean waterfromareliablesource
(e.g., fresh tap water);
￿ to use a new or disinfected container (cooker) and a new filter (cotton) to prepare drugs;
￿ to clean the injection site with a new alcohol swab before injection; and
￿ to safely dispose of syringes after one use.
2. Persons considering tattooing or body piercing should be informed of potential risks of acquiring
bloodborneinfections,whichcouldbetransmitted if equipmentis notsterile or if properinfection control
procedures are not followed (e.g., washing hands, using latex gloves and cleaning and disinfecting
surfaces)139 (BIII).
3. To reduce risks for acquiring bloodborne infections, patients should be advised not to share dental
appliances, razors or other personal care articles (BIII).
4. Although the efficiency of sexual transmission of HCV is low, safe-sexual practices should be encour-
agedforall HIV infected personsandbarrierprecautions(e.g., latex condoms)arerecommended toreduce
the risk for exposure to sexually transmitted pathogens (AII).
Prevention of disease
5. All patientswithHIV infection shouldbescreened for HCV infection (BIII).Screening is recom-
mended because some HIV-infected patients (e.g., injection drug users, and patients with
hemophilia) are at increased risk for HCV infection and HCV related disease, and because
knowledge of HCV status is important for management of all HIV-infected patients (e.g., to
interpret and manage elevated liver related tests). Screening should be performed by using
enzyme immunoassays (EIAs) licensed for detection of antibody to HCV (anti-HCV) in blood (BIII).
Positive anti-HCV results should be verified with additional testing (i.e., recombinant immunoblot assay
[RIBAÔ]orreverse transcriptasepolymerasechainreaction(RT-PCR)forHCV RNA). Thepresenceof
HCV RNA in bloodmightalso be assessed in HIV-infected personswith undetectableantibodybutother
evidence of chronic liver disease (e.g., unexplained elevated liver-specific enzymes) or when acute HCV
infection is suspected (CIII).
6. Persons coinfected with HIV and HCV should be advised not to drink excessive amounts of alcohol
(AII). Avoiding alcohol altogether mightbe prudentbecause it is unclear whether even occasional alcohol
use (e.g., less than 12 ounces of beer or less than 10 grams of alcohol per day) increases the incidence of
cirrhosis among HCV-infected persons (CIII).
7. Patients with chronic hepatitis C should be vaccinated against hepatitis A because a) the risk for
fulminant hepatitis associated with hepatitis A appears increased in such patients; b) hepatitis A vaccine is
safe for HIV-infected persons; and c) although immunogenicity is reduced in patients with advanced HIV
infection, more than two thirds of patients develop protective antibody responses (BIII). Prevaccination
screening fortotal(IgG andIgM)antibodytohepatitisAvirusiscost-effectiveandthereforerecommended
when greater than 30% prevalence of hepatitis A virus antibody is expected in the population being
screened (e.g., persons greater than 40 years of age)140. Patients should also be immunized for HBV
if they are susceptible (BIII).
8. HIV-HCV-coinfected patients may develop HCV associated liver disease over a shorter time
course than patients infected with HCV alone141–144and should be evaluated for chronic liver disease
and for the possible need for treatment. Limited data suggest that HCV treatment can be safely
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coinfectedpatients has notbeen established and many HIV-infected patients have conditionsthat compli-
cate therapy (e.g., depression), this care should occurin a clinical trial or becoordinated by providers with
experience treating both HIV and HCV infections (BIII).
9. In some studies, the incidence of antiretroviral-associated liver enzyme elevations has been increased in
patients coinfected with HIV and HCV142; such increases might not require treatment modifications.
Thus, although liver enzymes should be carefully monitored, HAART should not be routinely withheld
from patients coinfected with HIV and HCV (DIII). However, coinfected patients initiating HAART
might have an inflammatory reaction that mimics an exacerbation of underlying liver disease. In this
situation, careful monitoring of liver function is required.
Prevention of recurrence
10. If the serum HCV RNA level becomes undetectable during HCV therapy and remains undetectable
for 6 months after HCV therapy is stopped (sustained virologic response), greater than 90% of HIV-
uninfected patients with hepatitis C will remain HCV RNA negative for greater than five years and have
improved liver histology145. For HIV-HCV-coinfected patients, the durability of treatment response and
requirement for maintenance therapy are unknown.
Special considerations
Children
11. Transmission of HCV from mother to child appears to be more frequent for mothers
co-infected with HIV and HCV than for those infected with HCV alone. Therefore, children
born to women coinfected with HIV and HCV should be tested for HCV infection137 (BI).
Because maternal HCV antibody can persist for up to 18 months, testing should be performed at or after
two years of age. If earlier diagnosis is desired, RT-PCR for HCV RNA may be performed after one
month of age and should be repeated at a subsequent time. The average rate of HCV infection among
infantsbornto coinfectedwomen is approximately 15% (range, 5–36%)146. Data are limited on the natural
history of HCV infection and treatment of chronic hepatitis C in children. In addition, anmtiviral treat-
ment for chronic hepatitis C is not approved for patients < 18 years of age.
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APPENDIX
Recommendations to Help Patients Avoid Exposure to or Infection with Opportunistic Pathogens*
SEXUAL EXPOSURES
1. Patientsshouldusealatex condomduringeveryactofsexualintercoursetoreducetheriskforacquiring
CMV, HSV and HPV (AII). Condom use also will, theoretically, reduce the risk for acquiring human
herpesvirus 8, as well as super-infection with an HIV strain that has becomeresistant to antiretroviral drugs
(BIII) and will prevent transmission of HIV and other sexually transmitted pathogensto others (AII). Data
regardingtheuseand efficacyoffemale condomsare incomplete,butthese devices shouldbeconsideredas
a risk-reduction strategy (BIII).
2. Patients shouldavoid sexual practices that mightresult in oral exposureto feces (e.g., oral-anal contact)
toreducetherisk forintestinal infections(e.g., cryptosporidiosis,shigellosis, campylobacteriosis,amebiasis,
giardiasis andhepatitisA (BIII). Latexcondom use alone may notreduce theriskof acquiring these
fecal-orally transmitted pathogens, especially those which have low infectious doses. Persons
wishing to reduce their risk of exposure might consider using dental dams or similar barrier
methods for oral-anal and oral-genital contact, changing condoms after anal intercourse and
wearing latex gloves during digital-anal contact. Frequently washing hands and genitals with
warm soapy water during and after activities which may bring these body parts in contact with
feces may further reduce risk of illness. (CIII).
3. Hepatitis B immunizations is recommended for all susceptible (anti-HBc-negative)
HIV-infected patients (BII).
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men, as well as others with indications for HAV vaccine (BIII).
INJECTION DRUG USE EXPOSURES
1. Injection drug use is a complex behavior that puts HIV-infected persons at risk for HBV and HCV
infection, additional, possibly drug-resistant strains of HIV and other blood-borne pathogens. Providers
should assess the individual’s readiness to change this practice and encourage efforts to provide education
and support directed at recovery. Patients should be counseled to stop using injection drugs (AIII) and to
enter and complete substance-abuse treatment, including relapse prevention programs (AIII).
2. If they are continuing to inject drugs, patients should be advised (BIII)
￿ to neverreuse orsharesyringes, needles, water ordrugpreparationequipment;if,nonetheless,injection
equipment that has been used by other persons is shared, to first clean the equipment with bleach and
water (USPHS. HIV prevention bulletin:medical advice forpersonswhoinjectillicit drugs.Rockville,
Maryland: CDC, 1997);
￿ to use only sterile syringes obtained from a reliable source (e.g., pharmacies or syringe exchange
programs);
￿ tousesterile (e.g.,boiled)water topreparedrugs;if notpossible,touseclean waterfromareliablesource
(e.g., fresh tap water); to use a new or disinfected container (cooker)and a new filter (cotton)to prepare
drugs;
￿ to clean the injection site with a new alcohol swab before injection;
￿ to safely dispose of syringes after one use.
3. All susceptible injection drug users should be immunized against hepatitis B (BII) and
hepatitis A (BIII).
*Lettersandromannumeralsinparenthesesindicatethestrengthoftherecommendationandthequality
of evidence supporting it (see table 2).
ENVIRONMENTAL AND OCCUPATIONAL EXPOSURES
1. Certain activities or types of employment might increase the risk for exposure to tuberculosis (BIII).
These include volunteer work or employment in health-care facilities, correctional institutions, and
shelters forthehomeless, aswellasothersettingsidentifiedashighrisk bylocalhealthauthorities.Decisions
about whether to continue with such activities should be made in conjunction with the health-care
providerandshouldbebasedonsuchfactorsasthepatient’sspecificdutiesintheworkplace,theprevalence
of tuberculosis in the community, and the degree to which precautions designed to prevent the trans-
mission of tuberculosis are taken in the workplace (BIII). These decisions will affect the frequency with
which the patient should be screened for tuberculosis.
2. Child-careproviders andparentsofchildrenin childcare are at increased risk foracquiringCMVinfec-
tion, cryptosporidiosis, and other infections (e.g., hepatitis A and giardiasis) from children. The risk for
acquiring infection can be diminished by goodhygienic practices, such as handwashing after fecal contact
(e.g., duringdiaperchanging)andaftercontactwithurineorsaliva (AII).Allchildreninchild-carefacilities
also are at increased risk for acquiring these same infections; parents and other caretakers of HIV-infected
children should be advised of this risk (BIII).
3. Occupations involving contact with animals (e.g., veterinary work and employment in pet stores,
farms, or slaughterhouses) might pose a risk for cryptosporidiosis,toxoplasmosis, salmonellosis, campylo-
bacteriosis or Bartonellainfection.However, theavailable dataare insufficient to justify a recommendation
against work in such settings.
4. Contact with young farm animals, especially animals with diarrhea, should be avoided to reduce the
risk for cryptosporidiosis (BII).
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60 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY5. Hand washing after gardeningorothercontactwith soil might reduce therisk for cryptosporidiosisand
toxoplasmosis (BIII).
6. In areas endemic for histoplasmosis, patients should avoid activities known to be associated with
increased risk (e.g., creating dust when working with surface soil; cleaning chicken coops that are heavily
contaminatedwithcompostdroppings;disturbingsoil beneathbird-roostingsites; cleaning,remodelingor
demolishing old buildings; and cave exploring) (CIII).
7. Inareas endemic forcoccidioidomycosis,when possible, patientsshouldavoidactivities associated with
increased risk, including those involving extensive exposure to disturbed native soil (e.g., at building
excavation sites or during dust storms) (CIII).
PET-RELATED EXPOSURES
Health-care providers should advise HIV-infected persons of the potential risk posed by pet ownership.
However, they should be sensitive to the possible psychological benefits of pet ownership and should not
routinely advise HIV-infected persons to part with their pets (DIII). Specifically, providers should advise
HIV-infected patients of the following precautions (MMWR August 20, 1999).
General
1. Veterinarycareshouldbesoughtwhenapetdevelopsdiarrhealillness.Ifpossible,HIV-infectedpersons
shouldavoidcontactwithanimals thathavediarrhea(BIII). Afecalsampleshouldbeobtainedfromanimals
with diarrhea and examined for Cryptosporidium, Salmonella and Campylobacter.
2. Whenobtaininganewpet,HIV-infected patientsshouldavoidanimalsaged<6months(or< 1yearfor
cats;see Catssection),especially thosewith diarrhea (BIII). Becausethehygienicandsanitary conditionsin
pet-breeding facilities, pet stores and animal shelters are highly variable, the patient should be cautious
when obtaining a pet from these sources. Stray animals should be avoided. Animals aged <6 months,
especially those with diarrhea, should be examined by a veterinarian for Cryptosporidium, Salmonella, and
Campylobacter (BIII).
3. Patients should wash their hands after handling pets (especially before eating) and avoid contact with
pets’ feces to reduce the risk for cryptosporidiosis, salmonellosis, and campylobacteriosis (BIII). Hand
washing for HIV-infected children should be supervised.
Cats
4. Patients should be aware that cat ownership increases their risk for toxoplasmosis and Bartonella infec-
tion,as wellas enteric infections(CIII). Thosewhoelect toobtaina catshouldadoptorpurchaseananimal
that is aged > 1 year and in good health to reduce the risk for cryptosporidiosis, Bartonella infection,
salmonellosis and campylobacteriosis (BII).
5. Litter boxes should be cleaned daily, preferably by an HIV-negative, nonpregnant person; if the
HIV-infected patient performs this task, he or she should wash hands thoroughly afterward to reduce
the risk for toxoplasmosis (BIII).
6. Toreducetherisk fortoxoplasmosis,HIV-infected patientsshouldkeepcatsindoors,notallowthem to
hunt, and not feed them raw or undercooked meat (BIII).
7. Although declawing is not generally advised, patients should avoid activities that might result in cat
scratches or bites to reduce the risk for Bartonella infection (BII). Patients should also wash sites of cat
scratchesorbitespromptly(CIII)andshouldnotallowcatstolickthepatients’opencutsorwounds(BIII).
8. Care of cats should include flea control to reduce the risk for Bartonella infection (CIII).
9. Testing cats for toxoplasmosis (EII) or Bartonella infection (DII) is not recommended.
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10. Screening healthy birds for Cryptococcus neoformans, Mycobacterium avium or Histoplasma capsulatum is
not recommended (DIII).
Other
11. Contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) as well as chicks and ducklings
should be avoided to reduce the risk for salmonellosis (BIII).
12. Gloves should be used during the cleaning of aquariums to reduce the risk for infection with
Mycobacterium marinum (BIII).
13. Contact with exotic pets (e.g., nonhuman primates) should be avoided (CIII).
FOOD AND WATER-RELATED EXPOSURES
1. Raw or undercooked eggs (including foods that might contain raw eggs [e.g., some preparations of
hollandaise sauce, Caesar and certain other salad dressings, some mayonnaises, uncooked cookie and
cake batter, egg nog]); raw or undercooked poultry, meat, seafood (especially raw shellfish); and
unpasteurizeddairy products;unpasteurized fruit juice; and raw seed sprouts (e.g., alfalfa sprouts,
mung bean sprouts). Poultry and meat are safest when adequate cooking is confirmed with a
thermometer (internal temperature of 180 F for poultry and 165 F for red meats). If a
thermometer is not used, the risk of illness is decreased by consuming poultry and meat that
havenotraceofpink.Colorchangeofthemeat (e.g.,absence ofpink)doesnotalwayscorrelate
with internal temperature. Produce should be washed thoroughly before being eaten (BIII).
2. Cross-contamination of foods should be avoided. Uncooked meats should not be allowed to come in
contact with other foods; hands, cuttingboards, counters, and knives and other utensils should be washed
thoroughly after contact with uncooked foods (BIII).
3. Althoughtheincidenceoflisteriosis is low,it is a serious disease thatoccursunusuallyfrequently among
HIV-infected persons who are severely immunosuppressed. An immunosuppressed, HIV-infected
person who wishes to reduce the risk of acquiring listeriosis as much as possible may choose to
do the following:
(a) avoid soft cheeses (e.g., feta, Brie, Camembert, blue-veined and Mexican-style cheese such
as queso fresco). Hard cheeses, processed cheeses, cream cheese (including slices and spreads),
cottage cheese, or yogurt need not be avoided;
(b)cookleftoverfoods orready-to-eat foods (e.g.,hotdogs)untilsteaming hotbefore eating;
(c)avoidfoods from delicatessen counters(e.g.,prepared salads, meats,cheeses) orheat/reheat
these foods until steaming before eating;
(d) avoid refrigerated pates and othermeat spreads, orheat/reheat these foods untilsteaming if
eaten. Canned or shelf-stable pate and meat spreads need not be avoided;
(e) avoid raw or unpasteurized milk (including goat’s milk) or milk-products, or foods which
contain unpasteurized milk or milk-products. (CIII).
4. Patients shouldnotdrinkwater directly from lakesorrivers because oftherisk forcryptosporidiosisand
giardiasis (AIII). Waterborne infection might also result from swallowing water duringrecreational activi-
ties. Patientsshouldavoidswimming inwaterthatislikelytobecontaminated withhumanoranimalwaste
and should avoid swallowing water during swimming (BII).
5. During outbreaks or in other situations in which a community ‘boil water advisory’ is issued, boiling
water for 1 minute will eliminate the risk for acquiring cryptosporidiosis (AI). Using submicron,
personal-usewater filters(home/officetypes)and/ordrinkingbottledwater mightalso reducetherisk (see
Cryptosporidiosis section in Disease-Specific Recommendations for information on personal-use filters
and bottledwater) (CIII). Current dataare inadequateto supporta recommendation that all HIV-infected
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to take independent action to reduce their risk for waterborne cryptosporidiosis may choose to take pre-
cautions similar to those recommended during outbreaks. Such decisions are best made in conjunction
with a health-care provider. Persons who opt for a personal-use filter or bottled water should be aware of
the complexities involved in selecting the appropriate products, the lack of enforceable standards for
destructionorremoval ofoocysts,thecostoftheproducts,andthedifficultyofusingtheseproductsconsis-
tently. Patients taking precautions to avoid acquiring cryptosporidiosis from drinking water should be
advised that ice made from contaminated tap water also can be a source of infection (BII). Such persons
should be aware that fountain beverages served in restaurants, bars, theaters, and other public places might
also pose a risk, because these bever-ages, as well as the ice they might contain, are made from tap water.
Nationally distributed brands of bottled or canned carbonated soft drinks are safe to drink. Commercially
packaged noncarbonated soft drinks and fruit juices that do not require refrigeration until after they are
opened(i.e., thosethatcanbestored unrefrigerated ongroceryshelves) also are safe. Nationally distributed
brands of frozen fruit juice concentrate are safe if they are reconstituted by the user with water from a safe
source.Fruitjuicesthatmust bekeptrefrigerated fromthetime theyare processed tothetimeofconsump-
tion might be either fresh (unpasteurized) or heat-treated (pasteurized); only juices labeled as pasteurized
shouldbeconsidered free ofrisk fromCryptosporidium.Otherpasteurizedbeverages and beers are also con-
sidered safe to drink (BII). No data are available concerning survival of Cryptosporidium oocystsin wine.
TRAVEL-RELATED EXPOSURES
1. Travel, particularly to developing countries, might result in significant risks for the exposure of
HIV-infected persons to opportunistic pathogens, especially for patients who are severely immuno-
suppressed. Consultation with health-care providers and/or with experts in travel medicine will help
patients plan itineraries (BIII).
2. During travel to developing countries, HIV-infected persons are at even higher risk for foodborneand
waterborne infections than they are in the United States. Foods and beverages — in particular, raw fruits
and vegetables, raw or undercooked seafood or meat, tap water, ice made with tap water, unpasteurized
milk and dairy products, and items purchased from street vendors — might be contaminated (AII). Items
that are generally safe include steaming hot foods, fruits that are peeled by the traveler, bottled (especially
carbonated)beverages, hotcoffeeortea, beer,wine, and water broughtto a rollingboilfor1 minute(AII).
Treating water with iodine or chlorine might not be as effective as boiling but can be used, perhaps in
conjunction with filtration, when boiling is not practical (BIII).
3. Waterborneinfectionsmightresult fromswallowingwater duringrecreational activities. To reducethe
risk for cryptosporidiosis and giardiasis, patients should avoid swallowing water during swimming and
should not swim in water that might be contaminated (e.g., with sewage or animal waste) (BII).
4. Antimicrobial prophylaxis for traveler’s diarrhea is not recommended routinely for HIV-infected
personstravelling todevelopingcountries(DIII). Suchpreventive therapycan haveadverse effects and can
promote the emergence of drug-resistant organisms. Nonetheless, several studies (none involving an
HIV-infected population) have shown that prophylaxis can reduce the risk for diarrhea among travelers
(CDC. Health information for international travel, 1999–2000. Atlanta, Georgia: U.S. Department of
Health and Human Services, 1999:202). Under selected circumstances (e.g., those in which the risk for
infection is very high and theperiod of travel brief), the providerand patient may weigh thepotentialrisks
and benefits and decide that anti-biotic prophylaxis is warranted (CIII). For those persons to whom
prophylaxis is offered, fluoroquinolones (e.g., ciprofloxacin [500 mg daily]) can be considered (CIII),
although fluoroquinolones should not be given to children or pregnant women. Trimethoprim-
sulfamethoxazole (TMP-SMZ) (one double-strength tablet daily) also has been shownto beeffective, but
resistance to this drugis nowcommon in tropicalareas. Personsalready taking TMP-SMZ forprophylaxis
against Pneumocystis carinii pneumonia (PCP) might gain some protection against traveler’s diarrhea. For
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in prescribing this agent for prophylaxis of diarrhea because of the high rates of adverse reactions and the
possible need for the agent for other purposes (e.g., PCP prophylaxis) in the future.
5. All HIV-infected travelers to developing countries should carry a sufficient supply of an antimicrobial
agent to be taken empirically should diarrhea develop (BIII). One appropriate regimen is 500 mg of
ciprofloxacin twice a day for 3–7 days. Alternative antibiotics (e.g., TMP-SMZ) should be considered as
empirical therapy for use by children and pregnant women (CIII). Travelers should consult a physician if
their diarrhea is severe and does not respond to empirical therapy, if their stools contain blood, if, fever is
accompanied by shaking chills, or if dehydration develops. Antiperistaltic agents (e.g., diphenoxylate and
loperamide) are usedforthetreatment of diarrhea; however, they shouldnotbeused bypatientswith high
fever or with blood in the stool, and their use should be discontinued if symptoms persist beyond 48 h
(AII). Antiperistaltic agents are not recommended for children (DIII).
6. Travelers should be advised about other preventive measures appropriate for anticipated exposures
(e.g., chemoprophylaxisfor malaria, protectionagainst arthropodvectors, treatment with immune globu-
lin, and vaccination)(AII). They should avoid direct contactof the skin with soil or sand (e.g., by wearing
shoes and protective clothing and using towels on beaches) in areas where fecal contamination of soil is
likely (BIII).
7. In general, live-virus vaccines should be avoided (EII). One exception is measles vaccine, which is
recommended for nonimmune persons. However, measles vaccine is not recommended for persons who
are severely immunosuppressed (DIII); immune globulin should be considered for measles-susceptible,
severely immunosuppressed persons who are anticipating travel to measles-endemic countries (BIII).
Another exception is varicella vaccine, which may be administered to asymptomatic nonimmuno-
suppressed children (BII). Inactivated (killed) poliovirus vaccine should be used instead of oral (live)
poliovirus vaccine, which is contraindicated for HIV-infected persons. Persons at risk for exposure
to typhoid fever should be administered an inactivated parenteral typhoid vaccine instead of the live
attenuated oral preparation. Yellow fever vaccine is a live-virus vaccine with uncertain safety and efficacy
in HIV-infected persons. Travelers with asymptomatic HIV infection who cannot avoid potential
exposure to yellow fever should be offered the choice of vaccination. If travel to a zone with yellow fever
is necessary and vaccination is not administered, patients should be advised of the risk, instructed in
methods for avoiding the bites of vector mosquitoes, and provided with a vaccination waiver letter.
8. Ingeneral, killed and recombinant vaccines (e.g., diphtheria-tetanus,rabies, hepatitis A,hepatitisB,
Japanese encephalitis vaccines) should be used for HIV-infected persons just as they would be used for
non-HIV–infected persons anticipating travel (BIII). Preparation for travel should include a review and
updatingofroutine vaccinations, includingdiphtheria-tetanusforadultsand all routine immunizations for
children. Thecurrently available cholera vaccine is notrecommended for personsfollowinga usual tourist
itinerary, even if travel includes countries reporting cases of cholera (DII).
9. Travelers shouldbeinformed aboutotherarea-specific risksand instructed in waystoreducethoserisks
(BIII). Geographically focal infections that pose a high risk to HIV-infected persons include visceral
leishmaniasis (a protozoan infection transmitted by the sandfly) and several fungal infections (e.g.,
Penicilliummarneffeiinfection,coccidioidomycosis,andhistoplasmosis). Manytropicalanddevelopingareas
have high rates of tuberculosis.
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